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ABSTRACT
RELATIONSHIPS AMONG UNCERTAINTY, COPING, AND
PSYCHOLOGICAL DISTRESS IN OLDER ADULTS
WITH MILD COGNITIVE IMPAIRMENT

Jennifer Sjostedt Avery, MSN, RN, GNP-BC
Marquette University, 2014

Mild cognitive impairment (MCI) has an average prevalence of 18.9% and most
often affects people 60 years of age or older. It is a cognitive stage between normal
functioning and dementia (Petersen, 2003; Petersen, 2011; Petersen et al., 2014). MCI
can be broken into two subtypes classified by the presence of memory impairment
(amnestic MCI) or the lack thereof (nonamnestic MCI). Medical diagnostic criteria are
commonly used to guide research with older adults with MCI. A theoretical framework
that addresses the antecedents and consequences of MCI, specifically one examining the
relationships among MCI, uncertainty, coping and psychological distress, is essential to
guide the development of effective nursing interventions but is unapparent in published
literature.
The aims of this quantitative, cross-sectional study are to: (1) test select
components of a new conceptual framework for MCI by examining the relationships
among uncertainty, coping, psychological distress, time since diagnosis, and level of
cognitive impairment from MCI; (2) describe the levels of uncertainty, coping, and
psychological distress in persons with MCI; (3) examine the differences in scores on
uncertainty, coping, and psychological distress between the two subtypes of MCI; and (4)
examine the strength and direction of relationships between scores on uncertainty,
coping, and psychological distress within the subtypes of MCI.
The sample consisted of 91 primarily Caucasian (>85%) older adults receiving
care at a neurology clinic, with a relatively even split between genders and MCI subtypes.
Positive relationships were found between uncertainty, coping, and psychological
distress, supporting the study framework. In addition, subjects reported low to moderate
levels of uncertainty and psychological distress, and most often used emotion-focused
coping strategies. Subjects with naMCI reported more somatic symptoms than those with
aMCI (p<0.05); however, there were no significant relationships between the MCI
subtypes or level of cognitive impairment on the other psychological distress subscales,
coping instrument, or uncertainty instrument. The long-term goal of this study is to
provide a foundation for a program of research centered on the development and
evaluation of interventions to assist older adults who have a diagnosis of MCI and their
family members with coping and managing their condition.
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I. INTRODUCTION

Background and significance

The average lifespan in the United States is increasing; people can now expect to
live to be approximately 78.5 years-old (Arias, 2014). Concurrently, advances in science
have led to increases in quality of life through early identification of illnesses,
impairments, and other age-related changes. One such condition, mild cognitive
impairment (MCI), has become increasingly of concern as a potential pre-dementia
condition, making it a new target for early diagnosis and interventions to help maintain
quality of life through slowing or preventing the progression to dementia. MCI is
currently defined as functional impairment affecting mental processes, such as memory
or executive functioning, that is more than what is expected for normal aging and often
precedes dementia (Petersen, 2003; Petersen et al., 2014). It is generally diagnosed
starting around the age of 60 years (Petersen, 2011).
Diagnostically MCI can further be broken down into two subsets: Amnestic
versus non-amnestic MCI (Petersen, 2014). The main difference between these subsets is
the presence of memory impairment (amnestic or aMCI) or lack thereof (non-amnestic or
naMCI). Despite fundamental differences between aMCI and naMCI, there is a
significant lack of evidence for treating or screening one subset differently from the other
(Gauthier & Touchon, 2005; Lin, Vance, Gleason, & Heidrich, 2012; Ross & Bell, 2014).
In addition, older adults with either subtype of MCI are considered to be a vulnerable
population, at risk for coercion or mistreatment directly relating to their level of impaired
cognition, regardless of the nature of their impairment.
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Unfortunately, the point at which it is determined that changes in cognition are
being caused by MCI rather than normal age-associated changes or dementia is subjective
and not completely clear cut. In general, the diagnosis of MCI typically starts with the
patients’ or family members’ complaint of changes in cognition (Albert et al., 2011;
Petersen et al., 2014; Portet et al., 2006). This complaint is accompanied by a significant
difference in performance (within 1.5 standard deviations of what is normally expected
for age) on a brief cognitive screening tool such as the Montreal Cognitive Assessment
(Nasreddine et al., 2005) or Addenbrooke’s Cognitive Examination revised (Mioshi,
Dawson, Mitchell, Arnold, & Hodges, 2006).
Incidence and prevalence of MCI. Recently the average incidence rate and
prevalence for all types of MCI, calculated from 16 large scale studies, is estimated to be
47.9/1000 person-years and 18.9% respectively (Petersen et al., 2014). For aMCI and
naMCI separately, incidence rates are 3.8 and 3.9/100 person-years with prevalence of
11.6% and 9.9%, respectively (Katz et al., 2011). Comparatively, in the same study, for
all types of dementia the incidence rate was 2.9/100 person-years and prevalence was
6.5% (Katz et al., 2011). Higher rates of naMCI have also been found in persons who
identify as African American/Black compared to those who identify as Caucasian/White
(Katz et al., 2011; Lee et al., 2012). African American/Black race was also found to be a
significant risk factor for development of MCI in the Cardiovascular Health Study (Lopez
et al., 2003). Other studies have found conflicting results, with incidence rates of MCI
among Hispanic/Latino and African American/Black persons similar to the incidence
rates of MCI among Caucasian/White persons (Manly et al., 2008; Unverzagt et al.,
2011). These conflicting results suggest that the differences of MCI incidence by race
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may be contributed to increased misclassification of MCI (Kennedy, 2011). In general, it
has been estimated that MCI affects approximately up to one in five older adults globally
(Laino, 2011).
The general rate of progression from those diagnosed with either subset of MCI to
dementia is estimated to be between 5.9 to 10% per year (Gao et al., 2014; Petersen,
2011). However, the speed of progression (i.e. months versus years) from MCI to
dementia is inconsistent and difficult to predict (Portet et al., 2006). In addition, there is
little evidence to suggest which potential factors might influence or lead to one MCI
subset over another, or which factors might influence an older adult’s transition/speed
from MCI to dementia (Alzheimer’s Association, 2011). The higher incidence and
prevalence of MCI versus dementia, and the potential progressive relationship between
MCI and dementia highlights the possibility of a large portion of adults progressing from
MCI to dementia in the not so distant future. It suggests a need for increased primary
care visits to monitor potential progression from MCI to dementia, and increased use
anti-dementive drugs at an earlier stage.
Potential costs related to MCI. Overall the potential direct/indirect costs,
trajectory, and burden associated with MCI are not well understood and have only
recently been estimated in the United States (Lin & Neumann, 2013). Compared to older
adults without MCI or dementia in the US, those with MCI reported significantly
(p<0.001) higher rates of informal care use and substantially higher annual direct medical
costs (p<0.001) with a mean difference of $3,530 (Zhu et al., 2013). Another US-based
study also found that unspecified direct costs for older adults with MCI compared to
those without impairment (adjusted for age and gender) were significantly higher by an
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average difference of $859 per year (Leibson et al., 2012). However, in Germany, Luppa
et al. (2008) demonstrated a difference between the average direct costs from
outpatient/inpatient care, pharmaceuticals, medical supplies, home care, assisted living
and transportation for older adults with MCI at €4,443 (approximately $5,710) compared
to €3,814 (approximately $4,902) for those without MCI. While the 14% (€629, or
approximately $808) difference in mean costs might be clinically significant, the
difference was statistically insignificant (n = 413, p = 0.34).
Issues with MCI: Conceptualizations and definitions. Conceptualizations of
MCI stem from its’ evolving definitions branching from surrogate terms such as benign
senescent forgetfulness and age-associated memory impairment. These
conceptualizations of MCI are based on the assumption that a continuum of cognitive
functioning exists between normal aging and dementia (Petersen et al., 2014; Portet et al.,
2006). Originally, this continuum was based on diagnostic criteria with the assumption
of memory loss as the only source of impairment, and Alzheimer’s dementia reflecting
greater cognitive impairment on the continuum. Later the diagnostic definition of MCI
was broadened to include all types of cognitive impairment (aMCI and naMCI), thereby
introducing more heterogeneity in the theoretical continuum and relating MCI to all types
of dementia. Older adults transition along this continuum at differing, unpredictable
rates; and, not all older adults diagnosed with MCI continue on to AD. Some older adults
revert back towards normal functioning or stay stagnant within the scope of MCI (Anstey
et al., 2008; Banningh, Vernooij-Dassen, Rikkert, & Teunisse, 2008; Chertkow, 2002;
Costa et al., 2010; DeCarli, 2003; Diniz, Nunes, Yassuda, & Forlenza, 2009; Fisk &
Rockwood, 2005; Gauthier & Touchon, 2005; Lingler et al., 2006; Portet et al., 2006;
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Roach, 2005; Tuokko & Hultsch, 2006; Werner & Korczyn, 2008). For example, a
recent study of older adults diagnosed with MCI in primary care practices (n=357) found
that after 3 years, 41.5% of the sample reverted back to normal cognition, 21.3%
fluctuated between normal cognition and MCI, 14.8% were stagnant within MCI, and
only 22.4% had progressed to dementia (Kaduszkiewicz et al., 2014).
As a diagnostic entity, the definition of MCI has not always been straightforward
and clear cut, and a specific conceptual framework that encompasses attributes,
antecedents and consequences for MCI is nonexistent. Despite efforts to clearly and
uniformly define MCI, it is only recently that a diagnosis for MCI was accepted within
the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) (Matthews et
al., 2007; Rosenberg, Johnston, & Lyketsos, 2006). In May 2013, the DSM-V included
the diagnosis of “minor neurocognitive disorder” to encompass MCI, supporting it as its
own diagnosable entity (American Psychiatric Association [APA], 2013). However, it is
important to note that despite work towards the inclusion of MCI as a DSM-V diagnosis,
national or international guidelines specific to the management of MCI have not been
published (Bensadon & Odenheimer, 2013; Dean & Wilcock, 2012).
The historical lack of an accepted DSM diagnosis could be related to debates
about MCI as its own entity rather than simply a new label for early dementia or memory
loss associated with normal aging (Davis & Rockwood, 2004). Surrogate terms
(including but not limited to benign senescent forgetfulness, age-associated memory loss,
mild cognitive decline, and cognitive impairment, no dementia) have also added to the
varying definitions of MCI as either a process of aging or a pathological decline
(Matthews et al., 2007). Currently, the most widely accepted definition of MCI started to
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arise in the early 1990’s and is diagnostic: MCI represents a form of functional
impairment affecting mental processes, more than what is normally expected with age,
which often precedes dementia (Petersen et al., 2014; Petersen, 2003).
MCI is a useful concept to encompass the changes in cognition that are not the
result of aging or dementia. Yet, other than the aforementioned theoretical continuum of
cognitive impairment, a clear conceptual framework for MCI which addresses possible
antecedents and consequences is not apparent in published literature. The existing
theoretical continuum and diagnostic criteria only provide guidance about the trajectory
and attributes of MCI, not the antecedents or consequences of MCI. These attributes
contribute to understanding MCI but do not provide guidance for nursing interventions
that might help older adults with MCI and their families cope with the illness. Other
theories related to chronic illnesses have limitations for addressing the unique situation of
older adults with MCI (Corbin & Strauss, 1991, 1992; Lazarus & Folkman, 1984;
Levanthal, Meyer, & Nerenz, 1980; Mishel, 1988, 1990; Pearlin, Menaghan, Lieberman,
& Mullan, 1981; Pearlin & Schooler, 1978). For example, chronic illness theories do not
account for the unpredictable illness trajectory on consequences of having MCI or the
impact of cognitive impairment on the older adult’s appraisal of their situation.
Consequently, a conceptual framework that addresses antecedents and consequences
specific to MCI is needed in order to guide the development and evaluation of specific
interventions and further legitimize MCI as a target for research.
Conceptual framework for MCI. This study proposes the Sjostedt framework
for older adults with MCI (encompassing both aMCI and naMCI) that defines MCI as an
unstable state of limbo weighted by heterogeneity between older adults’ normal and
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abnormal continuums (normal aging versus dementia). While the entirety of the
framework is discussed in chapter two, the portion which will serve as the focus of this
dissertation will be briefly introduced now.
In the Sjostedt framework, the main consequence of MCI is uncertainty, which
then leads to the other consequences of coping and psychological distress. The
uncertainty from MCI stems mainly from aforementioned inconsistencies in MCI
diagnosis and variability in MCI trajectories. Uncertainty may then influence older
adults’ coping and psychological distress resulting from MCI. Coping and psychological
distress from MCI result as responses to diagnosis and symptoms related to MCI. Coping
may impact psychological distress, similar to the relationships between coping and
psychological distress with other chronic illnesses where emotion-focused and
dysfunctional coping have been positively correlated with psychological distress (Barron,
2000; Lauver, Kruse, & Baggot, 1999; Lynch, Kroencke, & Denney, 2001; SandersDewey, Mullins, & Chaney, 2001) and problem-focused coping negatively correlated
with psychological distress (Lynch et al., 2001; Sanders-Dewey et al., 2001). Finally, an
older adult’s progression with MCI or lack thereof over time may further shape the
consequences of MCI. The potential relationships of MCI, time, uncertainty, coping, and
psychological distress that will be tested in the Sjostedt framework are illustrated in
figure 1.
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Figure 1. Conceptual framework for the consequences of MCI.

Uncertainty, coping, and psychological distress with MCI. Uncertainty is
defined as an emotional state that occurs when a person is unable to assign definite value
to events or objects and/or is unable to predict an outcome (Mishel, 1983). MCI is often
referred to as an uncertain condition in qualitative studies of the experiences of older
adults with MCI, and within attempts to conceptualize, diagnose, and define MCI
(Bensadon & Odenheimer, 2013; Dean & Wilcock, 2012; Lu, Haase, & Farran, 2007;
Portet et al., 2006; Werner & Korczyn, 2008; Yanhong, Chandra, & Venkatesh, 2013).
Uncertainty can influence how older adults respond to any illnesses, treatments, and
hospitalizations (Landis, 1996). Within any chronic illness, uncertainty can stem from a
lack of clarity regarding symptoms, treatment options, disease etiology, and/or disease
prognosis (Mishel, 1983, 1988, 1999). Unlike other chronic illnesses, uncertainty from
MCI may stem from condition heterogeneity, varying trajectories, and inconsistencies in
diagnosis. Despite evidence from qualitative studies, no studies have quantitatively
assessed uncertainty from MCI.
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Coping is defined as the intentional cognitive and/or behavioral efforts to manage
internal or external demands appraised as exceeding the resources of or taxing the person
(Lazarus, 2000; Lazarus & Folkman, 1984). In the conceptual framework, coping results
as a response to MCI and uncertainty. Some older adults with MCI might use avoidance
oriented (or dysfunctional) coping through attempts to improve memory performance,
avoidance of activities to avoid making mistakes or masking of deficits (Banningh et al.,
2008). Yet, older adults with MCI might also use emotion-focused or problem-focused
coping through methods such as positive reframing, acceptance, religion, planning, and
instrumental support (McIlvane, Popa, Robinson, Houseweart, & Haley, 2008).
Uncertainty could affect an older adult’s ability to define and relate to MCI, thus
impairing their ability to cope effectively with it (Banningh et al., 2008; Blieszner,
Roberto, Wilcox, Barham, & Winston, 2007; Lingler et al., 2006; Lu et al., 2007).
Another result could be potential role and identity shifting, such as avoidance of
independence (Blieszner et al., 2007).
Finally, psychological distress might result from the diagnosis of MCI and is
likely influenced by uncertainty and coping. Psychological distress can be defined as the
physical, psychosomatic, or emotional reactions to a stressor which negatively affect a
person’s well-being (Kellner, 1987). Psychological distress from MCI may present as
emotions or reactions including anger, depression, anxiety, somatic symptoms, sadness,
frustration, loss of self-confidence, discouragement, loneliness, rejection, inactivity,
shame, self-blame, helplessness or loss of control (Banningh et al., 2008; Blieszner et al.,
2007; Carpenter et al., 2008; Dean & Wilcock, 2012; Ellison, 2008; Lu et al., 2007;
Pessin, Rosenfeld, Burton, & Breitbart, 2003; Petersen, 2003; Rosenberg et al., 2006).
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One study found that older adults with MCI were unable to identify any positive
consequences (Banningh et al., 2008). Yet, other studies have found positive emotions
stemming from MCI such as happiness or relief that the diagnosis is not dementia,
satisfaction from professional validation of their cognitive symptoms, optimism, and
comfort through being able to reduce uncertainty by attaching a name to their cognitive
symptoms (Dean & Wilcock, 2012; Lingler et al, 2006; McIlvane et al., 2008).
Uncertainty, coping and psychological distress with other conditions. To date,
no correlational studies exploring the relationships between MCI, uncertainty, coping,
and psychological distress exist. However, a variety of studies have examined these
relationships pertaining to adults with other chronic conditions (Haisfield-Wolfe et al.,
2012; Reich, Johnson, Zautra, & Davis, 2006; Landis, 1996; Lynch et al., 2001; Mullins
et al., 2001; Sanders-Dewey et al., 2001) and non-chronic situations and provide support
for the proposed hypotheses in the Sjostedt framework (Lauver et al., 1999; Taylor-Piliae
& Molassiotis, 2001). Levels of uncertainty concerning a chronic illness (HaisfieldWolfe et al., 2012; Landis, 1996; Lynch et al, 2011; Mullins et al., 2001) and emotionfocused coping strategies (Lynch et al., 2001; Sanders-Dewey et al., 2001) have been
significantly and positively correlated with psychological distress. Problem-focused
coping has been negatively correlated with psychological distress (Lynch et al., 2001;
Sanders-Dewey et al., 2001), and while clinically significant, this relationship is not
always statistically significant (Lynch et al., 2001).
In addition, another study found uncertainty to be positively and significantly
related to perceived inability to cope, and both variables were significantly and positively
correlated with increased levels of psychological distress among women receiving
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abnormal papanicolaou results (Lauver et al., 1999). However, this result conflicts with
that of Taylor-Piliae and Molassiotis (2001), who found no significant relationships
between uncertainty and coping, and no significant relationships between uncertainty or
coping and psychological distress among men receiving cardiac catheterization.
Differences in relationships among uncertainty, coping, and psychological distress as
demonstrated by Lauyer et al. (1999) and Taylor-Piliae and Molassiotis (2001) may be
attributable to gender, cultural, or illness differences.
Summary. Most previous studies focus on the diagnosis of MCI. Few studies
focus on the consequences for older adults with MCI. Consequences of having MCI
might include (1) uncertainty regarding diagnosis, condition trajectory, and treatment
(Bensadon & Odenheimer, 2013; Dean & Wilcock, 2012; Lu et al., 2007; Portet et al.,
2006; Werner & Korczyn, 2008); (2) coping with diagnosis and symptoms (Banningh et
al., 2008; McIlvane et al., 2008); and (3) psychological distress (Banningh et al., 2008;
Blieszner et al., 2007; Dean & Wilcock, 2012; Lu et al., 2007; Petersen, 2003). Older
adults’ responses to these consequences of having an MCI diagnosis are central to
nursing’s focus on holistic care. Understanding the consequences of having MCI is
foundational to designing effective interventions that help to decrease uncertainty and
facilitate coping with the condition.
Purpose of the study

This study is unique in quantitatively addressing consequences of MCI
(uncertainty, coping, and psychological distress), which have been overlooked or equated
with the consequences of dementia. This study will be foundational in validating a
conceptual framework that can guide the development of nursing interventions and
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further research for older adults with MCI. The purposes of this quantitative study are to:
(1) test select components of a new conceptual framework for MCI by examining the
relationships among uncertainty, coping, psychological distress, time since diagnosis, and
level of cognitive impairment from MCI, (2) describe the levels of uncertainty, coping,
and psychological distress in older adults with MCI; (3) examine the differences in scores
on uncertainty, coping, and psychological distress between the two subtypes of MCI; and
(4) examine the strength and direction of relationships between scores on uncertainty,
coping, and psychological distress within the subtypes of MCI.
Specific aims and hypotheses. The specific aims and hypotheses of this study
are:
Aim 1. Test select components of a conceptual framework for MCI by
examining the relationships among uncertainty, coping, psychological distress, time since
MCI diagnosis, and level of cognitive impairment from MCI.
H1. There will be a significant negative relationship between time since
diagnosis and level of cognitive impairment from MCI.
H2. There will be significant positive relationships between uncertainty and
coping.
H3. There will be significant positive relationships between uncertainty and
psychological distress.
H4. There will be significant relationships between coping and psychological
distress.
H5. The relationships between level of cognitive impairment from MCI and
coping will either be mediated or moderated by uncertainty.
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H6. The relationships between level of cognitive impairment from MCI and
psychological distress will either be mediated or moderated by uncertainty and
coping.
Aim 2. Describe the levels of uncertainty, coping, and psychological distress in
older adults with MCI.
Aim 3. Examine the differences in scores on uncertainty, coping, and
psychological distress between the subtypes of MCI.
Aim 4. Examine the strength and direction of relationships between scores on
uncertainty, coping, and psychological distress within the subtypes of MCI.
H7. There will be no significant differences between the subtypes of MCI in the
strength and direction of uncertainty, coping, and psychological distress.
The hypotheses of this study in relation to the conceptual framework are
summarized by figure 2 which displays the predicted relationships among variables
within the conceptual framework.

Uncertainty
(Aim3)

Time
since
diagnosis

- (H1)

MCI

+ (H3)

(Aim3, H6)

(Aim3, H5)

Psychological
Distress

+ (H2)

Coping

+/- (H4)

Figure 2. Predicted relationships between variables of the conceptual framework.
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Summary of key variable definitions. The conceptual definitions for MCI,
uncertainty, coping, and psychological distress can be summarized as follows:
MCI is an unstable state of limbo weighted by heterogeneity between older
adults’ normal and abnormal continuums (normal aging versus dementia).
Uncertainty is an emotional state that occurs when a person is unable to assign
definite value to events or objects and/or is unable to predict an outcome (Mishel,
1983).
Coping is the intentional cognitive and/or behavioral efforts to manage internal or
external demands appraised as exceeding the resources of or taxing the person
(Lazarus, 2000; Lazarus & Folkman, 1984).
Psychological distress is the physical, psychosomatic, or emotional reactions to a
stressor which negatively affect a person’s well-being (Kellner, 1987).
Significance to nursing and contribution to knowledge

With the growing population of older adults, nurses will be caring for more older
adults with MCI at various stages in a variety of environments. Specifically, the burden
of providing education about MCI to patients and providing support and guidance for
patients and family members is clearly within the scope of nursing. A validated
conceptual framework will not only provide guidance to nurses involved in research with
MCI, such a framework could also serve as a guide for designing patient and family
interventions for the management of MCI. The consequences for older adults with MCI
are central to nursing’s focus on holistic care. Understanding the consequences of having
MCI is foundational to designing appropriate interventions that help to decrease
uncertainty and facilitate coping with the condition.
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Potential for leading to future research. A validated conceptual framework for
MCI will guide future research through identifying areas for interventions. Most
published studies pertaining to MCI use only diagnostic criteria or do not specify a
framework as the basis for their research. While the current practice of using diagnostic
criteria to serve as a framework might help practitioners diagnose MCI, the current
criteria do not address the possible antecedents or consequences of MCI which limits the
potential scope of research and knowledge about how older adults with MCI respond to
their diagnosis.
Dissertation chapters overview

This chapter has focused on the significance of MCI, presentation of a portion of
a new conceptual framework for MCI, and introduction of the dissertation study’s aims,
and hypotheses. Chapter two will describe in more detail the historical shaping of MCI
definitions and conceptualizations, analyze existing chronic illness theoretical
frameworks and their limitations for MCI, then present the entirety of a new conceptual
framework for MCI. Chapter three will explicate the methodology that will be used to
accomplish testing of the new conceptual framework for MCI. Finally, chapters four and
five will present two different data-based manuscripts associated with this dissertation.
The first manuscript compared two commonly used instruments for the screening of MCI
in older adults (the Montreal Cognitive Assessment and the Revised Addenbrooke’s
Cognitive Examination), in order to provide evidence for which instrument might be
more appropriate for use in a primary care setting and this study. The second manuscript
presents the main findings related to the specific aims of the dissertation.
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II. REVIEW OF THE LITERATURE AND CONCEPTUAL-THEORETICAL

FRAMEWORK

This chapter will review literature pertaining to the conceptualization and
definition of MCI, limited applicability of theoretical frameworks related to chronic
illnesses and MCI, and the current status of knowledge related to the relationships
between MCI, time since diagnosis, uncertainty, coping, and psychological distress. This
chapter begins with a brief description of the literature search, followed by an overview
of the historical shaping of the definition and understanding of the concept of MCI.
Next, frameworks that have been used to guide studies related to chronic illness are
critiqued in relation to their applicability to older adults with MCI. The chapter then
concludes with an examination of literature supporting the proposed theoretical
framework for MCI, which will be tested in this study.
Literature search description

An extensive literature search was conducted using the CINAHL, Google-scholar,
Web-of-Science, ProQuest dissertations, and PubMed databases, followed by ancestral
searches of articles obtained from those databases. Initial searches were conducted
primarily for performing a concept analysis of MCI between August and November 2010
using only the terms “mild cognitive impairment.” This search yielded over 34,000
possible articles and books. The search was then narrowed down by year (with a focus
on literature from the last 10 years, aside from sentinel works), limited to English
language, and the main search term, “mild cognitive impairment,” was combined with
additional terms (or restricting terms) such as: MCI, pediatrics (to examine the use of
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MCI in other populations), geriatrics, chemotherapy, alcohol, nursing, perception and
concept. Surrogate terms for MCI were also searched to try to compile a comprehensive
collection of studies. Articles were included if they specifically addressed the concept of
MCI or the possible antecedents, attributes, and consequences of MCI. Articles were
excluded if they focused only on dementia rather than MCI. The inability to exclude
articles within the database searches (without accidentally excluding applicable articles)
pertaining only to older adults with dementia or only to caregivers of older adults with
MCI resulted in a lengthy search process and multiple duplicate articles or articles not
meeting the inclusion criteria. This search process was repeated in 2011, 2012, 2013, and
2014 to update the collection of articles and books to include recently published works
not present during initial searches.
The primary focus within the literature search was on MCI within the geriatric
population. This was later followed by focusing on MCI outside of the geriatric
population (i.e. pediatrics, or within patients suffering from “chemo-brain” or
alcoholism) to broaden the overall view of the concept for the purposes of creating the
conceptual framework. Articles were chosen based upon relevance to the concept and/or
diagnosis of mild cognitive impairment. Literature for the historical overview of MCI
came from articles used for the concept analysis of MCI.
Methods specified by Rodgers (Rodgers & Knafl, 2000) were used to guide the
concept analysis and literature search, with literature collection that focused on the
attributes, sociocultural, temporal, and discipline variations of MCI. The method can be
summarized as: (1) selecting a concept of interest; (2) identifying surrogate terms and
uses of the concept; (3) collecting relevant literature pertaining to all aspects of the
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concept; (4) identifying attributes of the concept then identifying the antecedents,
consequences, and other concepts related to the concept; and (5) drawing a conceptual
model connecting the attributes, antecedents, and consequences (Rodgers & Knafl, 2000).
Outside of literature pertaining specifically to MCI, additional searches were
conducted in the aforementioned databases to gather information on alternative
theoretical frameworks that might be applicable to this study. Again, the search was not
limited by year, but was limited to articles or books published in English. As MCI is
considered to be a chronic illness, the search focused on the following chronic illness
frameworks and their relation to MCI: (1) Pearlin and colleagues’ theories of coping
(Pearlin & Schooler, 1978) and stress (Pearlin et al., 1981), (2) Lazarus and Folkman’s
(1984) theory of Coping in Stress, (3) Corbin and Strauss’ (1991, 1992) Chronic Illness
Trajectory Framework, (4) Levanthal and colleagues’ (1980) Common Sense Model of
Illness Representations, and (5) Mishel’s (1988, 1990) theory of Uncertainty in Illness.
These frameworks were selected for their potential applicability to MCI and fit with
study variables.
Related concepts to MCI. While searching for conceptualizations of MCI,
several terms repeatedly arose within the literature search pertaining to memory.
Specifically the concepts of memory loss, memory impairment, or forgetfulness were
present in the majority of reviewed literature. The relationship of memory to MCI is
likely due to aforementioned the early conceptualizations of MCI as a pre-AD condition,
and hence only related to deficits in memory. There also appeared to be a major focus on
what MCI is not. MCI can be presented as an absence rather than presence of certain
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attributes, for instance the absence of functional impairment or absence of dementia
rather than solely the presence of cognitive decline.
Brief historical overview of conceptualizing and defining MCI

Defining MCI. In the past, MCI was broadly identified as the increased risk but
not definitive diagnosis of a neurodegenerative disease (Rosenberg et al., 2006). In this
manner, MCI encompassed any of the possible conditions between normal aging and
diagnosable cognitive decline (Diniz et al., 2009; Matthews et al., 2007; Roberts, Clare,
& Woods, 2009). In younger adults (less than 65 years old), MCI has been tautologically
defined as greater than normal cognitive impairment; seen as related to intelligence
(rather than aging), function and developmental progression (Byrne et al., 1987; Chen et
al., 2006; Hurria, Somio, & Ahles, 2007; Keefe, Eesley, & Poe, 2005). These previous
definitions of MCI resulted in several surrogate terms, including: Benign senescent
forgetfulness, age-associated memory impairment, late-life forgetfulness, agingassociated cognitive decline, age-related cognitive decline, mild cognitive decline,
questionable dementia, and mild neurocognitive decline (DeCarli, 2003; Ellison, 2008;
Matthews et al., 2007; Norlund et al., 2005; Rosenberg et al., 2006; Visser, 2006; Werner
& Korczyn, 2008). Cognitive impairment, no dementia (CIND) was also considered as a
surrogate term. However, not all patients who meet the criteria for CIND also meet the
criteria for MCI (Chertkow, 2002; Gauthier & Touchon, 2005). Surrogate terms have
added to the multiple definitions of MCI as either a process of aging or a pathological
decline (Matthews et al., 2007).
Starting around 1998 MCI began to be defined as a uniquely geriatric-condition,
thought to be related to dementia (Golomb, Kluger, & Ferris, 2004; Reisberg et al.,
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2008). Currently, the most widely accepted definition of MCI is diagnostic and comes
from the work of Dr. Ronald Petersen and colleagues: MCI represents a form of
functional impairment affecting mental processes, more than what is normally expected
with age, which often precedes dementia (Petersen, 2011; Petersen, 2003; Petersen et al.,
2014). Past efforts to define MCI were likely related to the desire to classify MCI as a
useful/diagnostic entity; allowing for more definitive selections of subjects for treatment
and research purposes. The philosophic underpinnings of MCI have also been largely
shaped by pragmatic views, which are reflected, if not directly stated, in most studies
(Fisk & Rockwood, 2005). Legitimization of MCI as a diagnosis (rather than broad
concept) also provides justification for reimbursement from payers for care services and
research funding for drug or other treatment studies (Werner & Korczyn, 2008).
Diagnostically MCI can further be broken down into two subsets: Amnestic
versus non-amnestic (Petersen et al., 2014). The main difference between the subsets is
the presence of memory impairment (amnestic or aMCI) or lack thereof (non-amnestic or
naMCI). Evidence suggests that those with aMCI are the most likely to later progress to
dementia, generally in the form of Alzheimer’s dementia (Davis & Rockwood, 2004;
Petersen & Morris, 2005). The general rate of progression from those diagnosed with
either subset of MCI to dementia is estimated to be between 5.9 to 10% per year (Gao et
al., 2014; Petersen, 2011). However, the speed of progression (i.e. months versus years)
from MCI to dementia is inconsistent and difficult to predict (Portet et al., 2006). In
addition, there has been little evidence to suggest which potential factors might influence
or lead to one MCI subset over another, or which factors might cause an older adult to
transition from MCI to dementia (Alzheimer’s Association, 2011).
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The presence of apolipoprotein (APOE) ε4 genotype, hippocampal atrophy
(estimated by hippocampal volume), and some cerebrospinal fluid (CSF) biomarkers
(Aβ42, T-tau, and P-tau) have been suggested to possibly predict increased likelihood of
transitioning from MCI to dementia (Farlow et al., 2004; Gomar, Bobes-Bascaran,
Conejero-Goldberg, Davies, & Goldberg, 2011; Hansson et al., 2006; Jack et al., 1999;
Mattsson et al., 2009; Okonkwo et al., 2011). Yet, studies evaluating the predictive
values of APOE ε4, hippocampal atrophy, and CSF biomarkers have only focused
predominately on older adults with aMCI (Ferreira et al., 2014). This focus on aMCI is
related to the similarities between aMCI and Alzheimer’s dementia (presence of a
memory deficit), and aforementioned likelihood of progression from aMCI to
Alzheimer’s dementia. Given study sample biases towards aMCI (Ferreira et al., 2014),
it is questionable if APOE ε4, hippocampal atrophy, and CSF biomarkers would also
effectively predict transitioning to dementia in older adults with naMCI. It is possible
that the predictive value of APOE ε4, hippocampal atrophy, and CSF biomarkers are not
unique to older adults with aMCI. Currently within clinical practice, APOE ε4,
hippocampal volume, and CSF biomarkers are not routinely being used to predict older
adults’ transitions from MCI to dementia given their low sensitivity and specificity as
diagnostic tests, and subsequently do not influence the nursing care of older adults with
MCI (Albert et al., 2011; Petersen & Trojanowski, 2009).
Conceptualizing MCI. Conceptualizations of MCI have been related to its’
evolving definitions branching from surrogate terms such as benign senescent
forgetfulness and age-associated memory impairment. Conceptualizing MCI is based on
the assumption that a continuum of cognitive functioning exists between normal aging
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and dementia (Portet et al., 2006). This continuum is best represented in a figure focused
on the relations between normal aging, MCI, and a type of dementia, Alzheimer’s
dementia (AD) from Petersen et al. (2001):

Figure 3. Continuum of cognitive impairment (Petersen et al., 2001).
Figure 3 does not distinctly note a direction, but instead implies a unidirectional
path from normal aging to AD. The progression of the path becomes more evident when
another figure from the same publication is considered that proposes a theoretical
negative relationship between age and cognitive functioning:

Figure 4. Theorized progression from MCI to AD (Petersen et al., 2001).
Yet, as previously stated, the path and speed of transition between normal aging
and dementia is uncertain. Older adults transition along the continuum at differing,
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unpredictable rates; and, not all older adults diagnosed with MCI continue on to AD,
some revert back towards normal functioning or stay stagnant within the scope of MCI
(Anstey et al., 2008; Banningh et al., 2008; Chertkow, 2002; Costa et al., 2010; DeCarli,
2003; Diniz et al., 2009; Fisk & Rockwood, 2005; Gauthier & Touchon, 2005; Lingler et
al., 2006; Portet et al., 2006; Roach, 2005; Tuokko & Hultsch, 2006; Werner & Korczyn,
2008). Additionally, this initial continuum from normal aging to MCI to dementia was
based on the assumption of cognitive impairment only affecting memory and thus only
relating to AD. However, later conceptualizations widened the scope to include all types
of cognitive impairment, and thus relating MCI to all types of dementia (Werner &
Korczyn, 2008). Outside of memory, MCI can affect an older adult’s executive
functioning, attention, use of language, and visuospatial skills (Norlund et al., 2005;
Petersen, 2011). In widening the scope of cognitive impairment, greater heterogeneity
was introduced to the concept, adding more variance to the possible speeds and trajectory
of the continuum and resulting in the subsets of aMCI and naMCI. Yet it is important to
note, despite the variability in the subsets, there is a significant lack of evidence for
treating or screening one subset differently from the other (Gauthier & Touchon, 2005;
Lin et al., 2012). In addition, older adults with either subtype of MCI are considered to
be a vulnerable population, at risk for coercion or mistreatment directly relating to their
level of impaired cognition, regardless of the nature of their impairment.
Select chronic illness theoretical frameworks

Although there is not a specific theoretical framework for MCI, other chronic
illness frameworks and theories exist that may be able to contribute to the understanding
of MCI. In this section, five frameworks will be described and critiqued for their
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relevance to MCI and this study. These frameworks include: (1) Pearlin and colleagues’
theories of coping (Pearlin & Schooler, 1978) and stress (Pearlin et al., 1981), (2) Lazarus
and Folkman’s (1984) theory of Coping in Stress, (3) Corbin and Strauss’ (1991, 1992)
Chronic Illness Trajectory Framework, (4) Levanthal, Meyer, and Nerenz’s (1980)
Common Sense Model of Illness Representations, and (5) Mishel’s (1988, 1990) theory
of Uncertainty in Illness.
Theories of coping and stress. Theories of stress and coping are frequently
used to guide research with older adults who have various types of chronic illnesses
(Lazarus & Folkman, 1984; Pearlin et al., 1981; Pearlin & Schooler, 1978). Two theories
of coping and stress developed by Pearlin and colleagues and one developed by Lazarus
and Folkman share some similarities in their limitations related to their applicability of
older adults with MCI. As such, these theories will be evaluated together, starting with a
brief presentation of each theory.
Pearlin and colleagues: Two theories of coping and stress. Pearlin and
colleagues provide two different yet connected theories pertaining to coping (Pearlin &
Schooler, 1978) and stress (Pearlin et al., 1981). First, coping is defined as a behavior
that serves to avoid being psychologically stressed or harmed by a problematic
experience (Pearlin & Schooler, 1978). These behaviors are separated into three distinct
categories: (1) behaviors that change a situation that is causing problems, (2) behaviors
that control the meaning of the situation after it occurs but before it causes the person to
experience stress, and (3) behaviors that serve to control stress after the situation has
occurred (Pearlin & Schooler, 1978). Coping is influenced by the social and
psychological resources available to the person, i.e. interpersonal networks with family
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and friends, and personality characteristics such as self-esteem, self-denigration, and
mastery (Pearlin & Schooler, 1978). The distinction between coping and psychological
resources acknowledges that coping is an intentional action that is affected by
predisposed or learned personality traits rather than being an unintentional personality
trait.
The efficacy of coping is determined by how well the person is able to avoid
stress (Pearlin & Schooler, 1978). Pearlin and Schooler (1978) suggest that using a
variety and large number of coping responses may be the most effective way to avoid
stress. This leads into Pearlin and colleagues’ (1981) next theory on the stress process.
Stress is defined as the multifaceted intentional and/or unintentional responses of a
person to a stimulus perceived as noxious (Pearlin et al, 1981). Sources of stress are life
events, life strains, and self-concepts (Pearlin et al., 1981). Coping and social supports
are then seen as mediating resources which can happen at any point during the process to
decrease stress (Pearlin et al., 1981). Stress can permeate the entire person resulting in
outcomes that are biochemical, physiological, or emotional manifestations (i.e. increased
blood pressure and depression). A simplified version of the stress version might look like
Figure 5:

LIFE
EVENTS
LIFE
STRAIN
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COPING
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Biochemical
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Emotional

Figure 5. Potential model of the Stress Process adapted from Pearlin et al. (1981).
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However, Pearlin and colleagues (1981) note from evaluating the connections
between sources of stress and increases or decreases in depression as a manifestation of
stress (or lack thereof), that the model is not simplistic as sources of stress may combine
to influence one another (Figure 6):

(+)

LIFE EVENT
Disrupted Job
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LIFE STRAIN
Change in Income

STRESS
Change in
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(+)
(-)
SELF-CONCEPT
Change in Mastery

(-)

SELF-CONCEPT
Change in Self-Esteem

(-)

(-)

(-)
(-)

Figure 6. Path model of sources of stress (Pearlin et al., 1981).
In addition, Pearlin and Schooler (1978) noted that coping is influenced by social
resources (i.e. social supports in the stress model). So finally, a more accurate
representation of Pearlin et al.’s theories of coping and stress might be illustrated by
Figure 7.
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Figure 7. Revised model of stress and coping adapted from Pearlin et al. (1978, 1981).
Previous uses and populations. The general theories of coping and stress from
Pearlin and colleagues (1978, 1981) have not been directly applied to research with older
adults with MCI. However, the theories have been applied to other chronic illnesses such
as cancer, (Dagan et al., 2011), diabetes mellitus (Bailey, 1996), depression (Penninx et
al., 1998), and HIV (Linn, Anema, Hodess, Sharpe, & Cain, 1996).
Relation to MCI. MCI could be seen as a condition which either serves as a life
event (receiving the diagnosis of MCI), life strain (adapting to cognitive impairments
from MCI), or something that affects a person’s self-concept, thus resulting in coping and
stress. However, Pearlin and colleagues’ theories assume that the life events or strains
are perceived as noxious in order to precipitate coping and stress. While it can be
assumed that older adults might perceive MCI as noxious, other research has suggested
that it can alternatively be perceived in a more positive manner for being a lack of
dementia (Lingler et al., 2006).
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Lazarus and Folkman: Coping in stress. Coping is defined within the theory of
Coping in Stress as the intentional cognitive and/or behavioral efforts to manage internal
or external demands appraised as exceeding the resources of or taxing the person
(Lazarus, 2000; Lazarus & Folkman, 1984). This view of coping obviously differs from
aforementioned view provided by Pearlin and Schooler (1978), where coping is perceived
as a method of avoidance rather than management of stress. Although it is not specified
if stress is negative, positive, or neutral. With the term “management,” it is implied that
stress is not uniquely positive, negative, or neutral. Always effective and always
ineffective coping strategies do not exist (Lazarus, 2000). In response to a stressor,
whether a coping strategy is effective or not depends on the person and the environment.
Figure 8 demonstrates these relationships:

Figure 8. Revised model of coping and stress (Lazarus, 1999).
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In the model, coping results in one or more of the following 15 categorical
emotional responses: guilt, shame, jealousy, hope, fright, relief, pride, happiness, sadness,
gratitude, compassion, anger, anxiety, envy, and love (Lazarus, 1999). In Lazarus’
(1999) revised model, appraisal directs how a person copes with stress, hence impacting
the outcome of emotional response(s). It also further supports the notion from Pearlin
and Schooler (1978) that coping is an intentional action as it requires the person to take
action in appraising the stressor.
Previous uses and populations. The framework provided by Lazarus and
Folkman (1984) has been used to guide a multitude of studies related to coping with other
chronic illnesses, including but not limited to: cancer (Felton & Revenson, 1984),
depression (Penninx et al., 1998), diabetes mellitus (Felton & Revenson, 1984),
hypertension (Felton & Revenson, 1984), psoriasis (Wahl, Hanestad, Wiklund, & Moum,
1999), and rheumatoid arthritis (Felton & Revenson, 1984; Walker, Jackson, &
Littlejohn, 2004). However, the theory of Coping in Stress has not been used as the
framework in research involving older adults with MCI.
Relation to MCI. In the theory of Coping in Stress, MCI could be seen as a
source that affects the antecedents of coping, such as by role shifting which may alter the
person’s beliefs of self and the world (Blieszner et al., 2007). In addition, unlike the
theories from Pearlin and colleagues, the framework provided by Lazarus and Folkman
does not assume that the event which triggers coping is noxious. In this way, coping can
also result from something that could be positive or neutral in nature rather than only
negative.
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Limitations of all three theories for this study. While somewhat different, all
three of the theories are helpful in explaining the relationships between coping and stress.
It is obvious with each framework that MCI may be seen as something that precipitates
coping and stress. Specific to the theories by Pearlin and colleagues, coping is
determined to be effective in the context of avoiding stress; whereas it might be more
appropriate to consider the efficacy of coping, as it is in Lazarus and Folkman’s
framework, in its ability to manage rather than avoid stress (as not all stress is avoidable).
Pearlin and colleagues’ theories also do not specify stress as either a positive or negative;
coping centers around the avoidance of stress, thereby suggesting that stress is only
perceived as something negative. Consequently the theories do not account for the
potential implications of positive stress (eustress) that could be experienced from
receiving a diagnosis of MCI (as opposed to dementia) and may be inappropriate for use
in evaluating stress and coping related to MCI.
A major limitation is that none of the three coping theories account for the effect
of cognitive impairment on appraisal leading to coping and stress, and these theories do
not consider the relationships between uncertainty, coping and stress. As previously
mentioned, older adults with MCI may lack awareness of their cognitive impairment(s)
(Tremont & Alosco, 2011), which could relate to a lack of awareness needed for
appraisal of stress in coping. This is not to say that those with MCI would be incapable
of appraisal, just that the appraisal may be impacted by MCI in a way that is unique from
other chronic illnesses. In addition, although uncertainty could also be interpreted as a
life event (Pearlin and colleagues) or related to personal resources (Lazarus and
Folkman), there is the question of the neutral, positive, or negative nature of uncertainty
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(and this relationship to stress and coping) which is not explicitly accounted for in the
stress and coping theories.
Chronic Illness Trajectory Framework. Corbin and Strauss’ chronic illness
trajectory framework provides an understanding of problems unique to the course of
chronic illnesses, and serves as a guide for the nursing management of chronic illnesses
(Corbin, 1998; Corbin & Strauss, 1991, 1992; Glaser & Strauss, 1968). Corbin (1998)
defines illness trajectory as the condition course and actions taken by participants (i.e.
patient, nurses, caregivers) to direct and control that course. It is broken down into nine
distinct phases which represent the different changes that occur within the course of
chronic illnesses, demonstrated within Figure 9, starting with pre-trajectory:

Pre-trajectory

Crisis

Trajectory onset

Comeback

Stable

Downward

Unstable

Death

Larger societal issues

Projected outcomes

Biographical factors

Acute

Figure 9. Trajectory phases of chronic illness adapted from Corbin (1998).
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It is important to note that although arrows are drawn to connect the phases in
Figure 9, a unidirectional path is not specified but implied through the numerical order
listed (Corbin, 1998; Corbin & Strauss, 1991, 1992). The shaping of an illness trajectory
is complex, requiring multiple resources and/or people. The trajectory phases (Figure 9)
are shaped within the context of projected outcomes, biographical factors, and larger
societal issues by management strategies (not in the Figure) that are not prescribed but
instead evolve over time to meet the needs of each phase (Corbin, 1998). The goals of
management strategies for each phase, and goal of definitions of the phases are explained
by Table 1 from Corbin (1998):
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Table 1. Trajectory phase definitions and management strategy goals from Corbin (1998).
Stage

Goal of definition

Goal of
Management

Pretrajectory

Genetic factors or lifestyle behaviors that place an individual or
community at risk for the development of a chronic condition.

Prevent onset of
chronic illness.

Trajectory
onset

Appearance of noticeable symptoms, includes period of diagnostic
workup and announcement of biographical limbo as person begins
to discover and cope with implications of diagnosis.

Form appropriate
trajectory
projection and
scheme.

Stable

Illness course and symptoms are under control. Biography and
everyday life activities are being managed within limitations of
illness. Illness management centers in the home.

Maintain stability
of illness,
biography, and
everyday
activities.

Unstable

Period of inability to keep symptoms under control or reactivation
of illness. Biographical disruption and difficulty in carrying out
everyday life activities. Adjustments being made in regimen with
care usually taking place at home.

Return to
stability.

Acute

Severe and unrelieved symptoms or the development of illness
complications necessitating hospitalization or bed rest to bring
illness course under control. Biography and everyday life activities
temporarily placed on hold or drastically cut back.

Bring illness
under control and
resume normal
biography and
everyday
activities.

Crisis

Critical or life-threatening situation requiring emergency treatment
or care. Biography and everyday life activities suspended until
crisis passes.

Remove life
threat.

Comeback

A gradual return to an acceptable way of life within limits imposed
by disability or illness. Involves physical healing, limitations
stretching through rehabilitative procedures, psychosocial coming
to terms, and biographical reengagement with adjustments in
everyday activities.

Set in motion and
keep going the
trajectory
projection and
scheme.

Downward

Illness course characterized by rapid or gradual physical decline
accompanied by increasing disability or difficulty in controlling
symptoms. Requires biographical adjustment and alterations in
everyday life activity with each major downward step.

To adapt to
increasing
disability with
each major
downward turn.

Dying

Final days or weeks before death. Characterized by gradual or rapid
shutting down of body processes, biographical disengagement and
closure, and relinquishment of everyday life interests and activities.

To bring closure,
let go, and die
peacefully.
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The goals of management present a problem for the assumed unidirectional path
of the model as they suggest that a person might be able to revert from certain stages (not
necessarily all stages) back into the stage that came directly before it or even further
back. For example, the goal of management for the unstable phase is to return to stability
(the phase that came before it) but the goal of management for dying is not to return to
the downward phase. Yet, in another example, the goal of management for the crisis
phase is to remove the life threat (causing the crisis phase), which suggests, if successful,
that person could possibly return directly to the stable or unstable phase, rather than
simply returning to the acute phase below it (such that if the life threat is removed,
symptoms might be resolved by its resolution, negating the acute phase).
Despite the question of a single or multidirectional path, it is a useful theory that
clearly identifies important areas for nursing intervention within each phase of a chronic
illness. Authors note that while the framework is general to all chronic illnesses, nurses
need to be flexible and able to individualize how they approach the framework for each
person (Corbin, 1998). This need for flexibility suggests that while a general path
connecting the chronic illness phases could be assumed, the questionable theory path is
not problematic as the path may be different dependent on the person, their condition(s),
and other outside influences (i.e. culture).
Previous uses and populations. While the Chronic Illness Trajectory
Framework has not been used in research involving older adults with MCI, it has been
used in relation to describing the transitions of older adults coping with other chronic
illnesses (Corbin, 1998). These conditions include, but are not limited to: AIDS/HIV
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(Nokes, 1998), multiple sclerosis (Gulick, 1998), rheumatoid arthritis (Shaul, 2012), and
stroke rehabilitation (Burton, 2001).
Relation to MCI. While MCI is a chronic illness whose trajectory may be
somewhat similar to that assumed in the Chronic Illness Trajectory Framework, it is
distinct from other chronic illnesses as it does not result in death, which completely
negates the last phase of the framework. Additionally, MCI is also a condition that does
not necessarily have a downward trend (necessary for phase progression in the Chronic
Illness Trajectory Framework). As previously stated in chapter one, not all older adults
with MCI have worsening cognitive impairment (or progress to dementia), some may
have improved cognition or remain stagnant.
Limitations of theory for this study. The Chronic Illness Trajectory Framework
has several aforementioned issues related to assumptions of MCI versus other chronic
illnesses. Additionally, the framework does not account for all variables being assessed
by this study. Specifically, the model does not account for the relationships of MCI to
uncertainty, coping, and psychological distress. It could be argued that uncertainty,
coping and psychological distress are projected outcomes which shape the MCI
trajectory. However, even under that assumption, the relationships between uncertainty,
coping, and psychological distress are not clearly defined.
Common Sense Model of Illness Representations. Levanthal’s Common Sense
Model dictates that people create mental representations of their illness through using
information available to them (concrete and/or abstract) to help them make sense of and
manage their illness (Levanthal et al., 1980). There are three sources for a person’s
available information: (1) lay sources, information provided through social contact and
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cultural knowledge; (2) external sources, parents, significant others, or authoritative
sources such as doctors; and (3) personal current experience with the illness (Hagger &
Orbell, 2003).
The mental representations can be considered both cognitive and emotional
representations and are generally composed of five themes: (1) Causes of the illness, (2)
consequences from the illness, (3) the perceived ability to control/cure the illness, (4)
identifying with the illness, and (5) the illness timeline (Hagger & Orbell, 2003). From
the representation, the person copes with their representation of the illness, and the
outcomes related to the illness. Emotional distress results from the emotional illness
representation, and can contribute to illness outcomes in the form of psychological
distress. These relationships are demonstrated by the graphical representation of the
theory in Figure 10.
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Figure 10. Graphical representation of Leventhal et al. (1980) Common Sense Model of
Illness Representations (Hagger & Orbell, 2003).
Previous uses and populations. The Common Sense Model has been applied in
three studies of older adults with MCI (Lin & Heidrich, 2012; Lin, Gleason, & Heidrich,
2012; Lingler et al., 2006). As demonstrated by a meta-analytic review of the Common
Sense Model (Hagger & Orbell, 2003), the framework has also been applied to describe
coping and psychological distress in multiple other studies including older adults with
chronic conditions, including but not limited to: Alzheimer’s dementia, chronic fatigue
syndrome, diabetes, HIV, irritable bowel syndrome, osteoarthritis, psoriasis, and
rheumatoid arthritis.
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Relation to MCI. In a grounded theory study (Lingler et al., 2006), authors
compared their results describing the process of making sense of a diagnosis of MCI to
the Common Sense Model. Authors concluded that there findings were similar to the
Common Sense Model in that assigning meaning to the diagnosis of MCI stems from the
older adult’s cognitive and emotional illness representations of MCI. However, the study
did not evaluate the outcomes of created illness representations (coping strategies, illness
outcomes, and psychological distress).
Lin and colleagues (2012) set out to describe the illness representations of MCI
and evaluate the illness representations for their relationships to demographic variables
and health history. Lin and Heidrich (2012) then took the application of the Common
Sense Model one step further, focusing on evaluating illness representations and their
impact on participant coping with MCI. Both studies included older adults with any
subtype of MCI; however, neither study reported the distribution of subjects with aMCI
versus naMCI, making it difficult to decipher if the results truly reflect both subtypes.
Findings from the studies demonstrated support for the Common Sense Model, yet
authors note that the directions of associations between illness representations differs
from some previous studies with other chronic illnesses. For example, emotional
representations of MCI varied greatly between individuals with many subjects having
few to moderate MCI symptoms and positive beliefs about MCI, unlike emotional
representations of other illnesses. This finding demonstrates a limitation of the Common
Sense Model for MCI in that older adults’ illness representations of MCI are unique from
illness representations of other chronic illnesses.
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Limitations of theory for this study. Aside from differences in the relationships
of the Common Sense Model for older adults with MCI compared to those with other
chronic illnesses, the main limitation of the Common Sense Model is the exclusion of
uncertainty. If one is uncertain about the themes that comprise the illness representation,
how does that affect coping and emotional distress? Uncertainty could be perceived as
contributive to the model, affecting both the cognitive and emotional illness
representations. Accounting for uncertainty in the common sense model may help with
understanding the uniqueness of coping and illness representations with MCI.
Uncertainty in Illness. Mishel’s (1988, 1990) theory of Uncertainty in Illness is
perhaps the most well-known and widely used mid-range nursing theory related to the
experience of uncertainty (Barron, 2000; Mast, 1995; Neville, 2003). The theory is not
focused on one age-group or population but can be split into uncertainty as it applies in
acute illness (Mishel, 1988, 1990, 1997) versus chronic illness (Mishel, 1990, 1999)
situations. The overall purpose of the theory is to help explain how persons with acute or
chronic illnesses cognitively process and construct meaning of their illness-related stimuli
(Mishel, 1990). A graphic model of this theory is presented by Figure 11.
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Figure 11. Mishel’s model of perceived uncertainty in illness (Barron, 2000; Mishel,
1988, 1990; Neville, 2003).
In the theory, uncertainty is defined as the emotional state that occurs when a
person is unable to assign definite value to events or objects and/or is unable to predict an
outcome (Mishel, 1983). Within chronic illness, it is expected that uncertainty is not
static but instead subject to change over time (Mishel, 1990). Additionally, with chronic
illness, uncertainty is seen as something that happens slowly over time, rather than
starting with one acute event (Mishel, 1999). Causes of uncertainty in chronic illness are
not fully explicated by the model (Figure 5), but are multifactorial and include: the nature
of illness (severity, erratic symptoms, and ambiguous symptoms), inability to predict the
future, concept of self, insufficient information, social support, health providers, and
personality disposition (Mishel, 1999).
Similar to appraisal for coping in the framework by Lazarus and Folkman (1984),
uncertainty is perceived as a neutral state until it is appraised by one of two processes to
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determine its value (demonstrated in Figure 5): inference and illusion (Mishel, 1990). It
could be argued that uncertainty is not neutral but always negative and should be avoided
or minimized whenever possible (Sheer & Cline, 1995). Yet, the view of uncertainty as
neutral until appraised has been supported by other authors (Hilton, 1994), and
highlighted in a concept analysis of uncertainty in illness by McCormick (2002).
Inference and illusion can be affected by the person, family, friends, and health
care professionals, and with chronic illness are also subject to change over time (Mishel,
1990; Padilla, Mishel, & Grant, 1992). Inference is the evaluation of uncertainty as either
a positive (opportunity) or negative (danger) state (Mishel, 1990). Illusion is the
construction of beliefs in the event of a situation with a negative trajectory, which allows
for uncertainty to be perceived as a potentially positive outcome (Mishel, 1990). If
uncertainty is appraised as a danger, coping strategies are employed to reduce the
presence of uncertainty. Similarly, if uncertainty is appraised as an opportunity, coping
strategies are employed to maintain rather than reduce uncertainty (Mishel, 1990). In
either event, if the coping strategies are successful, and uncertainty is reduced or
maintained as desired, adaptation is said to occur (Mishel, 1990).
Previous uses and populations. The theory of Uncertainty in Illness has not
been used in research involving older adults with MCI. However, the theory has been
used with older adults that have other chronic conditions to guide the evaluation of levels
of uncertainty, determine the effects of uncertainty, and guide development and
evaluation of interventions to decrease uncertainty. These conditions include but are not
limited to: atrial fibrillation (Kang, 2006; Kang, 2011), chronic hepatitis C (Bailey et al.,
2010), fibromyalgia (Anema, Johnson, Zeller, Fogg, & Zetterlund, 2009; Reich et al.;
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2006), human immunodeficiency virus (Brashers et al., 2003), Parkinson’s disease
(Sanders-Dewey et al., 2001), diabetes mellitus (Landis, 1996), rheumatoid arthritis
(Landis, 1996), and multiple types of cancer (Clayton, Mishel, & Belyea, 2006; Kazer,
Bailey, Sanda, Colbery, & Kelly, 2011; Lien, Lin, Kuo, & Chen, 2009; Padilla et al.,
1992; Sammarco & Konecny, 2010; Wallace, 2005). It is important to note that all of the
aforementioned conditions may involve the presence of physical pain or other outwardly
obvious physical symptoms (i.e. shortness of breath, palpitations, etc.), whereas MCI is a
condition that does not result in physical pain or involve outwardly obvious physical
symptoms. In addition, many of the aforementioned conditions involve a downward
trajectory with no chance of a return to normal functioning or stagnation, as may be seen
with MCI.
Relation to MCI. The progression of uncertainty in chronic illness proposed by
Mishel (1990, 1999) is similar to the theorized progression of MCI, where symptoms of
cognitive impairment do not necessarily start with an acute event but rather are slowly
progressive over time. As previously noted in chapter one, MCI is also a chronic
condition, like many other chronic illnesses, where symptoms, disease trajectory, and
treatment options can be extremely ambiguous and potentially resulting in uncertainty
alike the causes of uncertainty noted by Mishel (1999). Additionally, in her
reconceptualization of the theory of Uncertainty in Illness, Mishel notes that “when the
alternative is negative certainty, uncertainty becomes a preferable state” (Mishel, 1990,
258). This anecdote is apparent in a qualitative study of the experiences of older adults
with MCI where subjects noted being happy with the diagnosis of MCI as it is not the
diagnosis of dementia (Lingler et al., 2006). In this manner, while being diagnosed with
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MCI created uncertainty, older adults were able to use illusion to see this uncertainty as
an opportunity rather than danger because it was perceived as certainty the diagnosis was
not dementia.
Limitations of theory for this study. There are two main limitations of the
Uncertainty in Illness theory for this study: (1) fit of the theory with study variables, and
(2) theory assumptions. The Uncertainty in Illness theory would be a good fit for
directing this study if the presence of uncertainty and its relationship to coping and
psychological distress in older adults with MCI rather than the relationship of
uncertainty, coping, and psychological distress as interrelated consequences of MCI was
the only concern. While the theory of Uncertainty in Illness is useful to explain how an
older adult might experience or respond to uncertainty, it does not account for the
antecedents or consequences that may be unique to having a diagnosis of MCI. As noted
by Figure 5, cognitive capacities are accounted for and might impact the older adult’s
stimulus frame, but do not serve as the stimulus frame. What does this mean for the older
adult whose symptom pattern in the stimulus frame is from their cognitive capacities
rather than affected by it? In other words, what is uncertainty for the older adult whose
source of uncertainty might be their cognitive capacity rather than a more traditional
chronic illness symptom such as pain?
In addition, Mishel’s model assumes some level of awareness to be able to
appraise uncertainty. Older adults with MCI may lack awareness of their cognitive
impairment(s) (Tremont & Alosco, 2011), thus potentially lacking the awareness needed
to be able to appraise uncertainty. Also, if there is no awareness of the stimulus frame,
i.e. a lack of awareness resulting in an inability to recognize the symptom pattern, event
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familiarity or congruence, it is entirely possible that there is no stimulus to produce
uncertainty other than the stimulus provided by the introduction of being diagnosed with
MCI. This later becomes a problem for other variables in this study as the model only
accounts for coping and potentially psychological distress (from a lack of adaptation)
resulting from the appraisal of uncertainty.
Grounded Theory and MCI

There have been a few recent attempts to establish theories pertaining to MCI
which purported using grounded theory methodology from Corbin and Strauss (1990,
1998), and/or Glaser and Strauss (1967). These three qualitative studies (Banningh et al.,
2008; Beard & Neary. 2012; Lingler et al., 2006) provide insight into how older adults
experience, make sense of, or cope with their MCI diagnosis. Results of the studies
highlighted coping with MCI as a reaction to both the attributes of MCI (cognitive
impairment) and consequences from MCI (i.e. coping with negative emotions) (Banningh
et al., 2008; Beard & Neary, 2012). Older adults with MCI also demonstrate a wide
range of emotions (positive, negative, and neutral) in response to their diagnosis and
symptoms (Banningh et al., 2008; Lingler et al., 2006); however, they may not identify
with or fully understand their diagnosis (Beard & Neary, 2012; Lingler et al., 2006).
Finally, rather than a clear conceptual framework for MCI, these three studies only
provide themes to describe how older adults make sense of their diagnosis and cope with
MCI. The only study that relates their findings to a framework (the Common Sense
Model) was Lingler and colleagues (2006). In addition, all of the studies had small
sample sizes (< 20 subjects), and two of the studies excluded older adults with naMCI
(Banningh et al., 2008; Beard & Neary, 2012). Although the studies do not provide clear
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conceptual frameworks and have sample limitations, they provide rich description of
concepts central to the MCI experience and were influential on the development of a
conceptual framework for MCI.
Sjostedt’s conceptualization of MCI

The lack of a specific theoretical framework related to MCI and the limitations of
existing alternative frameworks related to chronic illnesses necessitate a new
conceptualization of MCI to provide support for research and the development of
interventions specific for older adults with MCI. Sjostedt’s new conceptualization of
MCI encompasses both subtypes. In this model, MCI is defined as an unstable limbo
weighted by heterogeneity between older adults’ normal and abnormal continuums
(normal aging versus dementia) rather than being solely linked to cognitive functioning.
Older adults with MCI teeter between these continuums, and can eventually progress to
dementia or revert back to normal functioning. Figure 12 demonstrates the complexity of
this conceptualization with its accompanying antecedents and consequences. In Figure
12, the antecedents for MCI are highlighted in green, the attributes highlighted in blue,
and the consequences highlighted in purple.
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Figure 12. The Sjostedt framework for MCI.
It is important to understand that the model is pliable, subject to change over time
and condition progression. As the unstable limbo implies, an older adult does not simply
get MCI at one point and then it goes away or always stays at that point. Additionally,
some antecedents, i.e. other chronic conditions, are subject to change over time which
may result in changes related to MCI. The theoretical framework is presented in detail
below, starting with the antecedents.
Antecedents. The antecedents for MCI are numerous—there is insufficient
evidence to suggest which antecedents might have more of an influence than the others
on the development or progression of MCI. Many of the reviewed studies assessed the
correlation of antecedents to MCI rather than predictive values of antecedents for MCI.
Hence the antecedents all may contribute in some way to MCI, but it is unclear how
much of the variance in MCI can be explained by each antecedent. MCI’s antecedents
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can be categorized into those that are modifiable, potentially-modifiable, or nonmodifiable.
Modifiable. Modifiable antecedents were identified as lifestyle factors, dietary
deficiencies, medications, and stress. With lifestyle factors and dietary deficiencies,
increased levels of physical exercise and some dietary modifications or supplements to
correct deficiencies have been shown to decrease symptoms of cognitive impairment
associated with MCI (Lake, 2006; Rosenberg et al., 2006). Physical exercise in mid-life
significantly reduces the risk of MCI later in life (Geda et al., 2010). Similarly, related to
exercise, obesity has been correlated with increased cognitive impairment (Farr et al.,
2008). Finally, dietary modifications such as strict adherence to the Mediterranean Diet
and supplements such as vitamins D and E to correct dietary deficiencies have been
correlated with lower incidences of MCI (Lake, 2006; Plassman, Williams, Burke,
Holsinger, & Benjamin, 2010; Rosenberg et al., 2006; Scarmeas et al., 2009).
Previous studies have demonstrated a relationship between MCI and “vascular
risk factors” such as midlife elevated serum cholesterol and blood pressure (Kivipelto et
al., 2001), but the relationship is not consistent (Plassman et al., 2010). Smoking is one
factor contributing to vascular risk that has been demonstrated to be predictive of
cognitive impairment within sizable populations, and place older adults at increased risk
for developing MCI (Cervilla, Prince, & Mann, 2000; Durazzo, Meyerhoff, & Nixon,
2010; Plassman et al., 2010). Another lifestyle factor, alcohol consumption, has also
been demonstrated to potentially contribute to the progression or lack of progression with
MCI (Anttila et al., 2004; Solfrizzi et al., 2007); but this result has been inconsistent
(Plassman et al., 2010).
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Similar to lifestyle factors and dietary deficiencies, regular medications and illicit
or recreational drugs are also potential risk for MCI (Hurria et al., 2007; Rogers, Wiese,
Rabheru, 2008; Shilling, Jenkins, & Trapala , 2006). NSAIDs and gonadal steroids have
been shown to possibly decrease risk of developing MCI, whereas other medications such
as statins and antihypertensives have no association or no consistent association with
MCI (Plassman et al., 2010). In addition, cognitive impairment related to medications
can be temporary, in which case an older adult may be inappropriately diagnosed with
MCI or it may be inappropriately determined that the older adult has progressed
completely from MCI to dementia. For instance, chemotherapy has been shown to
increase cognitive impairment, known as “chemo brain” or “chemo fog,” but is
oftentimes temporary (Hurria et al., 2007; Shilling et al., 2006).
Finally, stress is also a modifiable antecedent for MCI as it can be manifested as
impaired attention which may contribute to the symptoms of MCI (Chertkow, 2002;
Norlund et al., 2005). Stress reduction has been demonstrated to contribute to decreased
MCI symptoms (Troyer, Murphy, Anderson, Moscovitch, & Craik; 2008). Stress may be
present in many different forms, stemming from any aspect of an older adult’s life (i.e.
accepting a new job, moving, or death of a loved one). However, stress can also result
from the fear of cognitive impairment, likely associated with the stigmas surrounding the
diagnosis of dementia (Corner & Bond, 2004).
Potentially-modifiable. Potentially-modifiable antecedents were identified as
other chronic conditions, neuropsychiatric disorders or changes, and a lack of awareness
of deficits. Neuropsychiatric disorders such as depression can potentially be reversible
causes of MCI, where once treated, the older adult could return to normal cognition
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(Rosenberg et al., 2006). Yet, depression in particular, has been linked to increased risk
for MCI development (Plassman et al., 2010). There are also other chronic conditions
which, while not necessarily reversible, may be controllable such as hypertension,
diabetes, sleep apnea, schizophrenia, and other vascular diseases (DeCarli, 2003; Frisoni
et al., 2000; Gauthier & Touchon, 2005; Keefe et al., 2005). Finally, a lack of awareness
does not cause MCI, but it is seen as a precursor symptom to it, influencing how quickly
an older adult seeks treatment for MCI. Awareness could be the realization that the older
adult has become lost in a familiar place, personality changes, change in senses (such as
olfactory changes) or has decreases in usual activities (Blieszner et al., 2007; Chung &
Man, 2009; Devanand et al., 2000; Roberts et al., 2009). Increasing awareness of
changes in cognition could lead to earlier identification of MCI and impact consequences
related to MCI.
Non-modifiable. Finally, the non-modifiable antecedents could be categorized
into sociodemographic factors and neuropathologic changes. Sociodemographic factors
include but are not limited to educational level, age, race/ethnicity, and gender
(Chertkow, 2002; Plassman et al., 2010). Neuropathologic changes could potentially be
the result of Alzheimer’s dementia or other insults such as strokes and as such are nonmodifiable (DeCarli, 2003; Petersen et al., 2006; Visser, 2006).
Attributes. The first attribute of MCI is an “unstable limbo.” The majority of
articles refer to MCI in relation to dementia as a “transitional” state between normal
aging and abnormal aging (dementia), an incipient stage to dementia or a pre-dementia
stage. Many sources indicate that older adults with MCI are destined to have dementia
(Anstey et al., 2008; Banningh et al., 2008; Blieszner et al., 2007; Carpenter et al., 2008;
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Chertkow, 2002; Costa et al., 2010; DeCarli, 2003; Devanand et al., 2000; Diniz et al.,
2009; Ellison, 2008; Ellison, Harper, Berlow, & Zeranski, 2008; Fisk & Rockwood,
2005; Frisoni et al., 2000; Gauthier & Touchon, 2005; Lee et al., 2009; Lingler et al.,
2006; Matthews et al., 2007; Mattsson et al., 2009; Meyer, Xu, Thornby, Chowdhury, &
Quach, 2002; Narasimhalu, et al., 2009; Norlund et al., 2005; Paulsen & Duff, 2009;
Petersen, 2003; Petersen et al., 2006; Portet et al., 2006; Ready, Ott, & Grace, 2004;
Roach, 2005; Roberts et al., 2009; Rosenberg et al., 2006; Solfrizzi et al., 2007; Tuokko
& Hultsch, 2006; Visser, 2006; Visser, Scheltens, & Verhey, 2005; Werner & Korczyn,
2008). Yet, it is inaccurate to strictly refer to MCI as a “transitional” or other similar
state, as it implies only one possible outcome. As previously stated, MCI is not always
progressive; in many cases it can be stagnant or even revert back to “normal” cognition.
In this way, MCI is better seen as an unstable limbo which is capable but not necessarily
probable of tipping towards a normal or abnormal continuum but also possible to be
stagnating. Through viewing MCI as an unstable limbo rather than something definitively
progressive it is possible to reach new interventions; shifting the focus from the
prevention of dementia back to treatment of MCI.
The second attribute is a disconnection from normality resulting from physical,
mental, and emotional changes. This could be with regard to memory (Banningh et al.,
2008; Chertkow, 2002; Chung & Man, 2009; Diniz et al., 2009; Ellison et al., 2008; Fisk
& Rockwood, 2005; Gauthier & Touchon, 2005; Hurria et al., 2007; Matthews et al.,
2007; Narasimhalu, et al., 2009; Petersen, 2003; Petersen et al., 2006; Portet et al., 2006;
Rosenberg et al., 2006; Roberts et al., 2009; Shilling et al., 2006; Tuokko & Hultsch,
2006; Visser, 2006; Werheid et al., 2010), other functions of cognitive ability such as

52
intelligence (Byrne, Smith, and Backman, 1987; DeCarli, 2003), or expectations for how
the older adult “should” be, such as how one should age (Banningh et al., 2008; Blieszner
et al., 2007). Acquiring subjects in memory clinics has led to increased emphasis on the
memory disconnection as diagnostic criteria for MCI (Costa et al., 2010; Garand et al.,
2005; Devanand et al., 2000; Diniz et al., 2009; Ellison et al., 2008; Gauthier & Touchon,
2005; Mattsson et al., 2009; Visser et al., 2005; Werheid et al., 2010). Opening the
conceptualization to include other types of disconnect from normality highlights the need
for MCI identification within primary care—outside of memory clinics. However, for the
purposes of this study with the need to obtain a large sample of older adults diagnosed
with MCI, the focus of MCI will be on the mental disconnect from normality, which will
be assessed through subject performance on cognitive testing.
The third attribute is an absence of severe functional impairment and dementia
which is determined by clinical judgment (Banningh et al., 2008; Chertkow, 2002; Diniz
et al., 2009; Ellison et al., 2008; Gauthier & Touchon, 2005; Lee et al., 2009; Matthews
et al., 2007; Mattsson et al., 2009; Meyer et al., 2002; Petersen, 2003; Petersen et al.,
2006; Rosenberg et al., 2006; Tuokko & Hultsch, 2006; Visser, 2006). The absence of
severe functional impairment and dementia is evident through the presence of intact
“normal” activities of daily living. Although intact, some studies have demonstrated
minor impairments in “normal” activity areas of older adults with MCI such as
geographical orientation, speed, and multitasking (Banningh et al., 2008; Costa et al.,
2010; Visser, 2006); but, the impairments were not “severe.”
The last attribute is heterogeneity, which results in the varied trajectory of the
older adult with MCI to worsening cognition, stagnation, or improving cognition. Among
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older adults, MCI is recognized as having several different forms with a wide variety of
associated symptoms such as the differences mentioned between aMCI and naMCI, but
also where one older adult may have multiple impaired cognitive domains whereas others
may have only one (Anstey et al., 2008; Ellison et al., 2008; Fisk & Rockwood, 2005;
Gauthier & Touchon, 2005; Lingler et al., 2006; Matthews et al., 2007; Norlund et al.,
2005; Petersen, 2003; Petersen et al., 2006; Portet et al., 2006; Roach, 2005; Roberts et
al., 2009; Rosenberg et al., 2006; Tuokko & Hultsch, 2006). Contributing to
heterogeneity is the relationship of MCI to dementia, where some older adults with MCI
progress to dementia (worsening cognition), others stay always with MCI (stagnation),
and others still improve back towards normal cognitive functioning (improving
cognition) (Anstey et al., 2005; Banningh et al., 2008; Blieszner et al., 2007; Chertkow,
2002; Costa et al., 2010; DeCarli, 2003; Diniz et al., 2009; Fisk & Rockwood, 2005;
Frisoni et al., 2000; Garand, Dew, Eazor, DeKosky, & Reynolds, 2005; Gauthier et al.,
2006; Gauthier & Touchon, 2005; Lingler et al., 2006; Narasimhalu, et al., 2009;
Petersen et al., 2006; Portet et al., 2006; Roach, 2005; Roberts et al., 2009; Tuokko &
Hultsch, 2006; Visser et al., 2005; Werner & Korczyn, 2008; Zaudig, 1992). There is the
potential that the variability in MCI symptoms created by heterogeneity can also lead to a
lack of information or misdiagnosis, such as an erroneous diagnosis of dementia, in turn
causing increased stress for the patient and family (Banningh et al., 2008).
Some would argue that heterogeneity results in a need to treat each type of MCI
on a case by case basis as opposed to treating all types the same (Gauthier & Touchon,
2005). For example, it is possible that older adults with aMCI versus those with naMCI
may experience the consequences of MCI in different ways, given that those with aMCI
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are more likely to lack an awareness of their deficits (Tremont & Alosco, 2011).
However, there is opposition to this idea who believe that if treatment works for one type
of MCI it might work for all types (Roach, 2005). Current recommendations for nursing
care are consistent with this later view and do not vary based on MCI subtype (Lin et al.,
2012).
Consequences. In the Sjostedt model, the main consequence of MCI is
uncertainty, which leads to the other consequences of coping and psychological distress.
Yet, it is important to note that most of the evidence to support the consequences of MCI
comes from qualitative or limited descriptive studies. Therefore at this time, it cannot
fully be determined how the trajectory of MCI (worsening cognition, stagnation, or
improving cognition) impacts the consequences of MCI. In the model it is assumed that
the trajectory does not cause the consequences of MCI to differ (aside from the
progression towards a normal or abnormal continuum); that all older adults with MCI
will experience (in some way) the consequences of uncertainty, coping, and
psychological distress. In the future, longitudinal studies will be needed to determine the
impact of the trajectory on the consequences of MCI.
Uncertainty. MCI is often referred to as an uncertain condition within attempts
to both conceptualize and define it (Portet et al., 2006; Werner & Korczyn, 2008). The
attribute of heterogeneity results directly in uncertainty stemming from ambiguity,
confusion, and variability, impacting all of the consequences of MCI and leading to
differing opinions on diagnosis and selections of MCI populations (Anstey et al., 2008;
Banningh et al., 2008; Blieszner et al., 2007; Chertkow, 2002; DeCarli, 2003; Frisoni et
al., 2000; Gauthier & Touchon, 2005; Lee et al., 2009; Mattsson et al., 2009; Norlund et
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al., 2005; Paulsen & Duff, 2009; Tuokko & Hultsch, 2006; Visser, 2006; Werner &
Korczyn, 2008). Uncertainty can influence how older adults respond to illnesses,
treatments, and hospitalizations (Landis, 1996). Yet, uncertainty is not a phenomenon
unique to MCI. In general, uncertainty is said to occur when a person is unable to assign
definite value to events or objects and/or is unable to predict an outcome (Mishel, 1983).
Within any illness, uncertainty can stem from a lack of clarity regarding symptoms,
treatment options, disease etiology, and/or disease prognosis (Mishel, 1983; Mishel,
1988).
Qualitative studies about the experiences of living with MCI have provided
further evidence supporting the presence of uncertainty in MCI. Findings indicated that
uncertainty can greatly affect an older adult’s ability to define and relate to MCI
(Banningh et al., 2008; Blieszner et al., 2007; Lingler et al., 2006; Lu et al., 2007). In
addition, uncertainty about the nature of MCI was frequently identified, related to
symptoms of MCI being dismissed as normal ageing or dementia (Banningh et al., 2008;
Dean & Wilcock, 2010; Lu et al., 2007).
Nurses, physicians, and other practitioners can directly contribute to the presence
of uncertainty with MCI through variance in practice and dissemination of information
about MCI (Derksen, Graff, Visser, Vermooij-Dassen, & Rikkert, 2009). One study
found inconsistencies from participant report in the frequency of clinicians informing
them of their prognosis and likely condition trajectory (Derksen et al., 2009). Such
variance with resulting uncertainty can cause unjustified stress or anxiety for older adults
with MCI.
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Coping. It is proposed that coping will result from MCI, similar to the result of
coping with other chronic illnesses, but that coping may also result from or be shaped by
uncertainty. Within Mishel’s model of perceived uncertainty in illness, coping results
from either the danger or opportunity appraised from uncertainty (Mishel, 1988),
suggesting that coping might also result from or be shaped by the uncertainty resulting
from MCI. Uncertainty could affect a older adult’s ability to define and relate to MCI,
thus impairing their ability to cope with it (Banningh et al., 2008; Blieszner et al., 2007;
Lingler et al., 2006; Lu et al., 2007). An example would be avoidance oriented coping
through attempts to improve memory performance, avoidance of activities to avoid
making mistakes or masking of deficits (Banningh et al., 2008). Another result could be
potential role and identity shifting, such as avoidance of independence (Blieszner et al.,
2007).
Coping has been evaluated quantitatively in two studies involving older adults
with MCI (Lin & Heidrich, 2012; McIlvane et al., 2008). Using the Brief COPE,
findings from both studies indicated that older adults with MCI use significantly more
emotion-focused coping and problem-focused coping strategies in comparison to
dysfunctional coping strategies to manage with their MCI. Emotion-focused coping
strategies included positive reframing and seeking emotional support; problem focused
strategies included seeking out information or treatments; and dysfunctional strategies
included substance use, self-blame or behavioral disengagement (McIlvane et al., 2008).
Lin and Heidrich (2012) also found positive correlations between months since MCI
diagnosis and problem-focused coping (r = 0.31, p = 0.034) and dysfunctional coping (r
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= 0.64, p < 0.001). However, neither study evaluated the relationship between measured
cognitive impairment or other demographic variables and coping strategies.
Psychological distress. Psychological distress is the final consequence of MCI in
the Sjostedt framework and is influenced by uncertainty and coping. Psychological
distress was commonly identified through reactions such as anger towards self or family
members, sadness, loss of or low self-confidence or self-worth, loneliness, rejection,
inactivity, shame, self-blame, helplessness or loss of control and exacerbation of existing
relational problems (Banningh et al., 2008; Blieszner et al., 2007; Carpenter et al., 2008;
Ellison et al., 2008; Pessin et al., 2003; Petersen, 2003; Rosenberg et al., 2006). These
reactions are sometimes coupled with hypersensitive concerns of becoming a burden to
others, needing to abandon complex activities, or becoming overly aware to how others
react to the diagnosis (Banningh et al., 2008). Such responses can lead to increased
hostility within the family system, future-oriented worry, or impede rational decision
making (Pessin et al., 2003).
Although previous studies have not evaluated the relationships between
psychological distress, uncertainty, and coping in older adults with MCI, these
relationships have been examined in older adults with other types of chronic illness and
lend support to the hypotheses proposed in the Sjostedt framework. Psychological
distress has been demonstrated to be significantly and positively correlated with subjects’
levels of uncertainty and coping strategies with other chronic illnesses such as
fibromyalgia, diabetes mellitus, cancer, and multiple sclerosis (Anema et al., 2009;
Landis, 1996; Lien et al., 2009; Lynch et al, 2001; Mullins et al., 2011; Reich et al.,
2006). These relationships remained significant when controlled for subjects’
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educational levels (Lynch et al, 2001). Among individuals with Parkinson’s disease, one
study reported no significant relationship between psychological distress and uncertainty;
but a significant relationship between psychological distress and uncertainty for the
caregivers of those individuals (Sanders-Dewey et al., 2001). Yet it has also been
demonstrated that the relationship between uncertainty and psychological distress is
affected by whether or not the uncertainty is appraised as a danger or opportunity. Kang
(2006) demonstrated a significant negative relationship in patients with atrial fibrillation
between uncertainty being appraised as an opportunity and depression; and, a significant
positive relationship between uncertainty being appraised as a danger and depression.
Assumptions of the study

This study assumes that MCI is a diagnosable, and valid chronic condition that
does not cause physical pain or result in death. As a chronic condition it is expected that
the relationships demonstrated between psychological distress, uncertainty, and coping in
older adults with MCI may be similar to what has already been demonstrated in other
chronic conditions (Anema et al., 2009; Landis, 1996; Lien et al., 2009; Lynch et al,
2001; Mullins et al., 2011; Reich et al., 2006). Finally, consistent with current
suggestions for care, this study also assumes that while the subtypes of MCI may be
fundamentally different, nursing care related to MCI will not vary based on subtype (Lin
et al., 2012).
Summary

The current status of knowledge about MCI indicates diagnostic criteria clearly
delineate the attributes of MCI. However, a specific theoretical framework that addresses
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the relationships of antecedents and consequences of MCI, in particular the relationships
among uncertainty, coping, and psychological distress, is nonexistent. In addition,
frameworks pertaining to other chronic illnesses are limited in their applicability to older
adults with MCI as they do not account for the varying illness trajectory of MCI or
impact of MCI on appraisal of their situation. A framework that addresses the
relationships of antecedents and consequences of MCI is imperative to improve the care
of older adults with MCI through the development of effective nursing interventions.
This study will be foundational in quantitatively evaluating select components of the
Sjostedt framework with the goal of providing a theoretical base for effective
interventions and evidence-based practice specific to older adults with MCI.

60
III. RESEARCH DESIGN AND METHODS

This quantitative study used a descriptive correlational design. Data were
collected using one-time in-person interviews. The advantages of this study’s design are
the ability to demonstrate relationships among variables in the model, reduce dropout rate
related to single point data collection, and decrease missing data that might occur with
other survey methodologies (Polit & Beck, 2008). The limitations of this study’s design
are the inability to track participant changes over time, and the inability to identify causal
relationships among the variables (Polit & Beck, 2008).
Subjects and setting

Subjects. A convenience sample of 91 older adults from an outpatient neurology
clinic comprised the sample. Subjects were included if they were over 54 years of age,
had been given a diagnosis of MCI (either aMCI or naMCI) by their attending physician
based on neuropsychological testing, and could understand, speak and write in English.
Participants were excluded if they did not meet the above inclusion criteria, if their
physician suspected that other neuropsychiatric disorders or chronic conditions might be
complicating their diagnosis of MCI, or if they progressed from MCI to dementia.
Sample size. Analyses for aim 1 necessitate the largest sample, hence aim 1 was
used to guide the sample size estimation. Sample size was initially estimated using a
method from Cohen & Cohen (1983):
Effect size (f2) = R2 / (1 - R2) was calculated assuming a potential small squared multiple
correlation (R2) of 0.13
f2 = 0.13 / (1 – 0.13) = 0.15 (medium effect size)
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L determined from tables in Cohen & Cohen (1983), assuming a maximum of 12
variables (given the number of instrument subscales) and α = 0.05 for a power of 0.80
Estimated sample size (n*) = L / f2 +k (number of variables) + 1
n* = 17.34 / 0.15 + 12 + 1 = 128.6
In short, it was initially estimated that a sample of 129 older adults would yield a
power of 0.80 at α = 0.05. From experience in a previous study, it was estimated that the
neurology clinic on Thursdays would see an average 3 older adults per week with MCI.
From the clinic load, the resulting duration to achieve the desired sample size was
estimated to be 43 weeks. Unfortunately, sample accrual did not occur as quickly for the
main dissertation study as it was predicted from a previous study at the clinic. After 25%
of the initial sample was collected (n=33), preliminary analysis was performed to assess
the variables predicted for aim 1. It was determined from this analysis that the variables
related to MCI type, duration, and level of cognitive impairment were not strongly related
to the other main variables of uncertainty, coping, and psychological distress and should
not be included in the analysis for aim 1. By removing those variables from the model,
the sample size needed was recalculated. It was determined that only 91 people would be
needed to yield a power of 0.80 at α = 0.05.
Sampling procedure. Participant recruitment occurred over the course of 62
consecutive weeks (excluding federal-holidays or other weeks such as physician vacation
when the clinic was not operational) starting immediately after IRB approval. Potential
participants were identified prior to their scheduled appointment in the neurology clinic
by clinic staff. After completing their scheduled appointment with their physician, all
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potential participants were invited to participate and instructed to contact Jennifer
Sjostedt, RN, GNP-BC if they had an interest in participating in the study.
If the potential subject expressed interest, Sjostedt discussed the study in detail
with them and (when present) their family caregiver(s). After discussion of the study
details, if the potential subject was willing to participate and met inclusion criteria, the
informed consent process immediately followed. Data collection then began after written
consent was obtained.
Setting. The sample for the study was recruited from a clinic in the area that
specializes in the diagnosis of MCI (the Memory Disorders Clinic at Froedtert Hospital /
Medical College of Wisconsin). The Memory Disorder Clinic (MDC) was chosen for its
volume of patients with MCI. A preliminary cognitive screening instrument study by
Sjostedt and Dr. Malgorzata Franczak at the MDC was able to recruit on average 3
subjects per week after a < 10% refusal rate (total of 49 subjects in 4.5 months) with a
relatively equal amount of aMCI or naMCI diagnoses. The clinic is part of an academic
facility focused on research located in Milwaukee, WI and serves Milwaukee, Waukesha,
Ozaukee, Kenosha and Racine counties in Wisconsin. Between 30% to 75% of clinic’s
target population (dependent by county) are considered to be members of minority
populations (Froedtert Hospital, 2011). It is expected that study participants from the
clinic reside mainly in a diverse, urban, mid-western area of the United States, and the
results of this study may not be applicable to other populations (such as those in rural
communities).
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Instruments

All instruments in this study were selected to be consistent with the conceptual
definitions of the variables, and their reliability and validity (see summary of
psychometrics and expected data in table 1). Instruments to assess the study variables by
order of administration were: Montreal Cognitive Assessment (level of cognitive
impairment from MCI), a Demographic Survey, Uncertainty Stress Scale (uncertainty),
Brief COPE (coping), and Kellner Symptom Questionnaire (psychological distress). The
demographic survey measured time since initial MCI diagnosis in months and years, and
select antecedents which could potentially have an effect on uncertainty, coping, and
psychological distress: subject gender, age, race/ethnicity, educational level, marital
status, religious affiliation, and socioeconomic status. The demographic survey was
administered as part of the in person interview; however, time since initial MCI diagnosis
was obtained from the participant’s electronic medical record by Sjostedt after
completing the in person interview.
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Table 2. Theoretical constructs, instruments, and reliability by order of administration.

Theoretical

Instrument

Scale

α*

Expected
Data

Montreal Cognitive
Assessment
(MoCA)

11 items
0-30

0.83

Scale Level

Not Available

Nominal and
Ordinal
Level

0.92-0.96

Scale Level

0.50-0.90

Scale Level

0.76-0.95

Scale Level

Construct
Cognitive
Impairment

points
Select MCI
Antecedents

Demographic Survey

10 items
N/A
points

Uncertainty

Uncertainty Stress Scale
(USS)

59 items
0-397
points

Coping

Brief COPE

28 items
0-84
points

Psychological

Symptom Questionnaire
(SQ)

92 items
0-92

Distress
points

*MoCA (Nasreddine et al., 2005), USS (Agretelis, 1999; Barron, 2000; Ford, 1989),
Brief COPE (Carver, 1997; Lin & Heidrich, 2012; McIlvane et al., 2008), SQ (Bull, Luo,
& Maruyama, 1994; Williams, 1993)
Montreal Cognitive Assessment (MoCA). MCI was operationalized by the
level of cognitive impairment determined using the MoCA (Nasreddine, 2011). The
MoCA was developed to be sensitive enough to detect subtle changes in cognition
associated with MCI, easy to use/interpret, and could be administered within a short time
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frame (Nasreddine et al., 2005). Outside of testing within memory clinics, the MoCA has
been used to test for MCI in populations ranging from persons with subacute stroke or
transient ischemic attacks (Dong et al., 2010; Pendlebury, Cuthbertson, Welch, Mehta, &
Rothwell, 2010), to those with other cardiovascular diseases (McLennan, Mathias,
Brennan, & Steward, 2011) or Parkinson’s disease (Chou et al., 2010; oops et al., 2009;
Nazem et al., 2009).
The initial instrument was tested with a sample of 46 patients with either MCI or
AD and 46 healthy controls. After testing, the instrument was revised to the “final”
version and retested with a larger sample of 94 older adults with MCI, 93 older adults
with AD, and 90 health controls (Nasreddine et al., 2005). It does not appear that the
final version of the MoCA was revised beyond the initial report revisions.
The first version of the MoCA assessed 10 different cognitive domains, but was
later limited to 8 domains (11-items, 30-points) after it was concluded that 5 items did not
discriminate well between MCI, dementia, and healthy controls (Nasreddine et al., 2005).
The 8 domains included in the final version include: Short term memory, visuospatial
abilities, executive functioning, attention, concentration, working memory, language, and
orientation. The final version of the MoCA was first validated in both English and
French (in Canada), and is now available in over 31 different languages (Nasreddine,
2011; Nasreddine et al., 2005); a copy of the English version and scoring instructions are
included in the appendix.
Psychometrics. The sensitivity and specificity of the MoCA for identifying MCI
with a cut-off score of 26 was reported as 90% and 87% respectively (Nasreddine et al.,
2005), which has since been closely replicated in other studies (Smith, Gildeh, &

66
Holmes, 2007). Item analysis demonstrated differences between participants with
dementia versus those with MCI and normal cognition; supporting the MoCA’s ability to
detect slight differences in cognition. Specifically, participants with dementia performed
more poorly than those with MCI (and those with MCI more poorly than participants
with normal cognition) on items assessing visuospatial abilities, executive functioning,
short-term memory, and orientation (Nasreddine et al., 2005).
The resulting positive and negative predictive values for MCI with the MoCA
were 89% and 91% respectively (Nasreddine et al., 2005). In a comparison between a
widely used tool for dementia screening (the Mini-Mental State Exam, MMSE) and
MoCA with a sample of 93 participants with MCI, 73% of participants scored within the
“abnormal” range (<26 points) on the MoCA but in the normal range (≥26 points) on the
MMSE (Nasreddine et al., 2005). A similar trend was found in other samples of people
who had either an acute stroke, transient ischemic attacks or Parkinson’s disease, where
32% to 58% of the subjects who had normal MMSE scores scored within the abnormal
range on the MoCA (Dong et al., 2010; Nazem et al., 2009; Pendlebury et al., 2010). In
addition to supporting the MoCA for identifying MCI, these results highlight the
limitations of the MMSE for differentiating between MCI and normal cognition.
The MoCA appears to have good internal consistency, with a Cronbach’s alpha of
0.83 (Nasreddine et al., 2005). Similar Cronbach’s alpha levels ranging from 0.74 to 0.83
have also been reported for the Japanese and Arabic language translations of the MoCA
(Fujiwara et al., 2010; Rahman & El Gaafary, 2009). Test-retest reliability also has been
demonstrated with a small sample (15 older adults with MCI and 20 health controls),
finding no significant differences in how either group scored on the MoCA between
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initial testing and a 1-month follow up with the same test (Ahmed, de Jager, & Wilcock,
2012).
Construct validity of the MoCA was not reported by the instrument authors
(Nasreddine et al., 2005). Only one study presented a factor analysis of the MoCA, and
the results were unclear and difficult to interpret (Berstein, Lacritz, Barlow, Weiner, &
DeFina, 2011). Despite the lack of factor analysis, several other studies have supported
the face validity of the MoCA (Chou et al., 2010; Dong et al., 2010; Hoops et al., 2009;
McLennan et al., 2011; Nazem et al., 2009; Smith et al., 2007); likely related to the high
aforementioned predictive validity (sensitivity and specificity of the instrument for
detecting MCI). The high sensitivity and specificity of the MoCA demonstrates its
ability to correctly identify and rule-out MCI (to measure what it was made to measure);
adequately providing evidence for its clinical validity.
Limitations. Authors reported that the initial instrument development was based
on the “clinical intuition” of their initial study’s main author (Nasreddine et al., 2005).
Given the lack of clarity or framework with MCI conceptualization, diagnosis, and
language; clinical intuition might not have been the most appropriate initial method of
development. In addition, low Cronbach’s alpha (0.55) was reported for the MoCA when
used in a sample from a cardiac and diabetic/endocrine outpatient clinic in Australia;
suggesting that it may be inappropriate to use the MoCA with that population (McLennan
et al., 2011). Another study also reported lower standardized coefficient alphas ranging
from 0.66 to 0.77 for the MoCA, after calculating a MoCA score for participants from
other existing data from population or volunteer samples of health older adults or those
with known or suspected brain pathology (Bernstein et al., 2011); although the alpha
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levels could potentially be related to data collection methods. In addition, many other
studies that have used the MoCA did not report reliability statistics (Dong et al., 2010;
Hoops et al., 2009; Nazem et al., 2009; Pendlebury et al., 2010; Smith et al., 2007).
Consequently, the lower alpha levels and lack of reliability statistics support the need for
further in-depth evaluations of the reliability of the MoCA.
Uncertainty Stress Scale (USS). The USS was chosen to measure uncertainty
from MCI as it does not contain items on uncertainty related to physical pain. The USS
was developed based on a prior mixed methods study by Hilton using the community
version of Mishel’s Uncertainty in Illness Scale (MUIS) and qualitative interviews
(Hilton, 1994). The USS was created to meet the needs specified within the qualitative
interviews that were not addressed in the MUIS; specifically the USS measures
uncertainty in illness-related situations and the stress, threat, or positive feelings
generated by uncertainty. The USS has not been used in research involving older adults
with MCI or any other type of cognitive impairment. However, the USS lends itself to
research in uncertainty with MCI as it does not focus on uncertainty related to physical
pain.
The USS can be separated into 2 sub-scales, one focused on uncertainty and the
other focused on stress from uncertainty. Both scales were used in this study. The USS
contains 54 items where subjects are asked to rate on a 0 to 4 (none to very high) or N/A
Likert-scale their level of uncertainty related to a statement such as “I am uncertain
whether changes in my mild cognitive impairment (MCI) will be detected early.” After
rating their uncertainty, the subject then rates their stress from that uncertainty on a 0 to 2
(none or very low to high or very high). After the 54 items, there are 4 additional items
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that ask the subject to place an X on a line indicating their overall uncertainty, overall
stress related to uncertainty, overall threat related to uncertainty, and overall positive
feelings from uncertainty. There is also one yes/no question asking subjects if they have
any positive feelings from their uncertainty. Higher numbers on the scale equate to
higher levels of uncertainty and/or stress.
Psychometrics. Hilton’s 1994 article discussed in detail the narrowing down of
the USS to its current fourth version. Unfortunately, the only reported measure of
internal consistency in Hilton (1994) comes from one of the previous iterations of the
USS in Ford (1989), where the Cronbach’s alpha was reported as acceptable, 0.92 for the
total scale. The most recent version of the USS, used in this study, has been reported as
having acceptable internal consistency of 0.95 on the uncertainty subscale and 0.97 on
the stress subscale (Agretelis, 1999; A. Hilton, personal communication, October 15,
2012).
Limitations. The biggest limitations are the lack of published support for use of
the USS and lack of studies involving older adults with MCI and the USS. The USS was
originally designed for use in persons with cancer but has been adapted to fit other
populations. The USS in this study was reworded with permission from the author (A.
Hilton, personal communication, October 15, 2012) using the published cancer USS
(Hilton, 1994), where MCI replaced the word cancer. This study may help to validate use
of the USS in condition, such as MCI, where other uncertainty measures may be
inappropriate because physical pain and medications or treatments resulting from the
condition are near to non-existent.
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Brief COPE. The Brief COPE is the only measure of coping that has been used
in older adults with MCI. It is also shorter than other available instruments to measure
coping, which will help to prevent test fatigue from the multiple instruments in this study.
The Brief COPE contains 28 items which assess fourteen coping reactions (with two
items for each for each reaction): active coping, planning, positive reframing, acceptance,
humor, religion, using emotional support, self-distraction, denial, venting, substance use,
behavioral disengagement, and self-blame (Carver, 1997). The fourteen coping reactions
can be reduced into three sub-scales of coping: (1) emotion-focused coping (acceptance,
emotional support, positive reframing, religion, and humor), (2) problem-focused coping
(active coping, planning, instrumental support), and (3) dysfunctional coping (selfdistraction, venting, self-blame, behavioral disengagement, denial, and substance use)
(McIlvane et al., 2008). Initially, items on the Brief COPE were scored on a 0-3 scale
where 0 = I haven’t been doing this at all and 3 = I’ve been doing this a lot (Carver,
1997). However, a 4-point scale where 1 = I haven’t been doing this at all and 4 = I’ve
been doing this a lot has also been used (McIlvane et al., 2008).
For this study, subjects were asked to complete the entirety of the Brief COPE by
responding to the following with regard to each of the items: “The next set of questions
asks you about ways that you have coped with your cognitive impairment over the past
month. In the past month, how often have you done the following things to cope with
your cognitive impairment?” Each item will then be graded by the subject on the
aforementioned 3-point scale. The rationale for using the 3-point scale rather than
alterative 4-point scale is to allow the study results to be comparable to recent research
involving coping in older adults with MCI, where the 3-point scale was used (Lin &
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Heidrich, 2012). With the Brief COPE both grading scales have demonstrated acceptable
internal consistency, which is discussed below.
Psychometrics. The current version of the Brief COPE (Carver, 1997) resulted
from a factor analysis and item reduction from the original COPE inventory by Carver et
al. (1989). Carver (1997) demonstrated acceptable internal consistency with the Brief
COPE in a convenience sample of 168 participants from a community affected by a
hurricane. Cronbach’s alpha was reported for each of the fourteen coping reactions
(Carver, 1997) and ranged from 0.50 (venting) to 0.90 (substance use).
For older adults with MCI, McIlvane et al. (2008) found acceptable internal
consistencies on the sub-scale measures of the Brief COPE: 0.80 (emotion-focused
coping), 0.88 (problem-focused coping), and 0.62 (dysfunctional coping). Authors also
reported reliability statistics for their comparison group of care partners for older adults
with MCI, which also demonstrated acceptable internal consistencies: 0.84 (emotionfocused coping), 0.88 (problem focused coping), and 0.81 (dysfunctional coping).
Another study of older adults with MCI (Lin & Heidrich, 2012) also found acceptable
internal consistency on the sub-scales: 0.77 (emotion-focused coping), 0.88 (problemfocused coping), and 0.73 (dysfunctional coping). However, neither pre nor post power
analyses were reported in either of the studies. Consequently, it is possible that the
demonstrated Cronbach’s alphas are related to the smaller sample sizes in McIlvane et al.
2008 (n = 46 older adults with MCI and 29 care partners) and Lin and Heidrich 2012 (n =
63 older adults with MCI).
Limitations. Only two studies have been published where the Brief COPE was
used in older adults with MCI, and both studies used differing grading criteria for the
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scale items. While this study will help to further validate the use of the Brief COPE with
a larger sample of older adults with MCI using the original grading criteria, it is also
considered a limitation. Another limitation is the instrument’s ability to assess coping at
one point in time rather than over time. To assess coping with MCI over time an
additional study will need to be conducted which longitudinally evaluates coping.
Symptom Questionnaire (SQ). Kellner’s (1987) SQ has been widely used since
its initial publication to operationalize psychological distress in older adults. The SQ has
not been used in research involving older adults with MCI; however, the SQ is brief and
contains simple to follow yes/no or true/false items (Kellner, 1987). The SQ was used in
its entirety in this study. The SQ was developed from the Symptom-Rating Test (SRT)
(Kellner & Sheffield, 1973) to evaluate psychological distress. Unlike the questions on
the SRT, the SQ contains brief items to which subjects respond yes/no or true/false. The
items on the SQ were developed based on a review of literature on neuropsychological
symptoms in normal controls and psychiatric patients, followed by statements selected
from interview between investigators and neurotic patients or those with personality
disorders (Kellner, 1987).
The SQ consists of 92 dichotomous items of which 68 items indicate symptoms of
psychological distress and 24 items are antonyms indicating psychological well-being
(Kellner, 1987). The items can be separated into four main subscales of depression,
anxiety, anger-hostility, and somatic. These four subscales can then further be divided
into symptom (depressive symptoms, anxiety symptoms, anger-hostility symptoms, or
somatic symptoms) or wellbeing (contented, relaxed, friendly, somatic well-being)
subscales for a total of eight possible subscales. For the symptom subscales, the items
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are all either yes/no or true/false and scored as 0 = no or false, and 1 = yes or true with a
maximum score of 17, with higher scores indicating more distress. On the well-being
subscales, the items are reverse coded (0 = yes or true, and 1 = no or false) with a
maximum score of 6, and again with higher scores indicating more distress.
Psychometrics. Criterion-related validity was established through using the SQ
to differentiate between normal controls or people receiving treatment for their
psychiatric condition to those with untreated psychiatric conditions, and through
correlating the SQ scales to other existing instruments such as the Hopkins Symptom
Checklist and the Hamilton Rating Scale for Depression (Kellner, 1987). Reliability of
the SQ was demonstrated by Kellner (1987) using test-retest reliability, where after 2
weeks the split-half reliability of change in each scale for persons who were anxious and
depressed (n = 22) was +0.92 (anxiety), +0.94 (depression), +0.91 anger-hostility, and
+0.86 (somatic). Kellner (1987) also reported the conventional split-half reliability of the
scales in other studies to be: +0.75 to +0.95 (anxiety), +0.74 to +0.93 (depression), +0.78
to +0.95 (anger-hostility), and 0.57 to 0.84 (somatic). Cronbach’s alpha for the four
main scales and total scale with adults were not reported by Kellner (1987) but has been
reported elsewhere and found to be sufficient: ranging between 0.83-0.95 for depression,
0.76-0.92 for anxiety, 0.91-0.93 for anger-hostility, 0.90-0.92 for somatic, and 0.80 for
the total scale (Bull, 2011; Bull et al., 1994; Lewis et al., 2009; Williams, 1993).
Limitations. Alike the instrument for uncertainty, the SQ has not been used in
older adults with MCI. It is possible that the psychometrics of the SQ may be different in
older adults with MCI compared to normal older adults. In addition, despite the
simplicity of the instrument, it is a lengthy instrument and survey fatigue may be a factor
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when giving this instrument last. This will be limited by providing subjects with breaks
in between instruments, and frequently reminding subjects that they may stop the study at
any point.
Procedure

Data collection. Sjostedt completed the Collaborative Institutional Training
Initiative (CITI) program, institutional offered Health Insurance Portability and
Accountability Act (HIPAA) training, and National Institute of Health (NIH) protecting
human research participants training prior to beginning the study. Data were collected in
person by Sjostedt as described within the above section on sampling procedure. Date of
diagnosis of MCI was obtained from the participant’s electronic medical record by
Sjostedt after completing the in person interview. Data and consent forms was recorded
using paper and pen. Caregivers when available were present during the informed
consent process and study at the request of the participant. After informed consent,
subjects completed the MoCA followed in order by the (1) demographic questionnaire,
(2) USS, (3) Brief COPE, and (4) SQ.
As part of a normal clinic appointment, subjects received the Addenbrooke’s
Cognitive Exam revised (ACE-R). Consequently, only portions of the MoCA which are
not repetitive of those in the ACE-R were completed for the study, and the subjects were
asked for permission to obtain the results of the ACE-R from their clinic record.
Repetitive sections in the MoCA that were excluded and instead obtained from the ACER include: cube copy, clock draw, serial 7’s, and orientation (date, month, year, day,
place, and city). When the ACE-R was not completed during the subjects’ appointment,
the MoCA was given in its entirety.
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The responses were transferred into a password-protected electronic data file by
Sjostedt and original papers filed in a locked file-box for the remainder of the study (after
which time they will be shredded). Other than signatures required on the consent form,
all remaining forms and electronic copies were assigned an arbitrary number to help
protect subject confidentiality. This data management procedure is described in detail
below.
Data management and analysis

Data management. Data were abstracted by Sjostedt directly from completed
paper records of the participant interview into an Excel spreadsheet on an encrypted 4 Gb
flash-drive dedicated solely to the research project. After paper records were entered into
the electronic system, they were kept in a locked file-box until they can be destroyed.
The Excel spread sheet had cell-parameters set to help minimize data entry errors; as data
were entered, numbers which are outside of the cell parameters or are potentially outliers
were highlighted and researcher prompted to recheck the data. Collected data did not
include any participant-identifying information; subsequently, there will be no way to
link collected data back to individual participants in the final data-set. In addition, all
Microsoft Word and Excel files were assigned an additional password (different from that
of the flash-drive) to provide further protection against any loss of confidentiality. After
collection was completed, responses were entered into an Excel file an subsequently
imported into SPSS for analysis. All paper data and consent forms will be destroyed after
3 years, and unidentifiable electronic files will be kept indefinitely.
Expected data. Aside from the demographic questionnaire, responses from each
instrument were summed to result in scale level data as follows: (MoCA) the sum of
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correct responses on the MoCA, (USS) the sum of item responses on the subscales of
uncertainty and stress, (Brief COPE) the sum of item responses on the subscales of
emotion-focused coping, problem-focused coping, and dysfunctional coping, and (SQ)
the sum of item responses for each of the subscales: depression, anxiety, anger/hostility,
and somatic.
Analysis. Data analysis was performed using SPSS statistical software. All data
were assessed for frequencies, mean, median, mode, outliers (scatter plots), skewness and
kurtosis. Prior to conducting data analysis to meet the study aims, differences related to
demographic variables (i.e. gender) on the other variables of level of cognitive
impairment from MCI, subtypes of MCI, time since initial diagnosis with MCI,
uncertainty, coping, and psychological distress were examined using one-way analysis of
variance or χ² tests as appropriate. Any differences related to demographic variables
were considered as possible confounding variables within the remaining analyses to meet
study aims. Below is a detailed description of the specific statistical analyses that were
conducted to assess each study aim:
Aim 1 with related hypotheses. Test select components of a conceptual
framework for MCI by examining the relationships among uncertainty, coping,
psychological distress, time since MCI diagnosis, level of cognitive impairment from
MCI, and (if determined appropriate in the analyses for aims 3 and 4) subtypes of MCI.
Hypotheses 1 through 6 dictate the expected relationships within the Sjostedt framework,
as demonstrated by Figure 2 in Chapter 1. Structural equation modeling (SEM) was
considered as potential method for evaluating the fit of variables within the framework.
However, SEM is unlikely to demonstrate the unique contributions of each of the
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subscales, which is especially important when evaluating the variable of coping. Instead,
to evaluate this aim and the associated hypotheses predicting relationships within the
conceptual framework, multivariate hierarchical regression analyses were used with each
psychological distress subscale as a separate dependent variable, and the scales associated
with uncertainty (first block) and coping (second block) as the independent variables.
The variables of time since diagnosis, level of cognitive impairment from MCI, and
subtype of MCI were also considered as potential independent variables in the regression
analyses predicting psychological distress. However, preliminary analyses demonstrated
a lack of significant relationships between the outcome variables and time since
diagnosis, level of cognitive impairment from MCI, and subtype of MCI. Given the lack
of significant relationships, and concerns related to the speed of sample accrual, the
variables of time since diagnosis, level of cognitive impairment from MCI, and subtype
of MCI were excluded from the final regression analyses.
It was suspected that coping might act as either a moderating or mediating
variable between uncertainty and psychological distress (anxiety, anger/hostility,
depression, and somatic symptoms). An example of these potential relationships is
demonstrated by figure 13:
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MODERATION: Uncertainty

MEDIATION:

Coping

Uncertainty

Psychological Distress

Psychological Distress
Coping

Figure 13. Moderation vs. mediation of coping between uncertainty and psychological
distress.
Barron and Kenny’s (1986) approach for assessing moderation/mediation was
followed to determine if the relationships between uncertainty and psychological distress
are moderated or mediated by coping.
Aim 2. Describe the levels of uncertainty, coping, and psychological distress in
older adults with MCI. This aim was addressed by calculating response frequencies,
means, and descriptive statistics. Following assessment of variable frequencies, outliers
(scatter plots), skewness and kurtosis, reliability statistics were conducted for each of the
instrument sub-scales and whole scales.
Aim 3. Examine the differences in scores on uncertainty, coping, and
psychological distress between the subtypes of MCI. This aim was addressed by
calculating t-tests or one way analysis of variance to evaluate the differences between
group means (subtypes of MCI) on time since diagnosis, uncertainty, coping, and
psychological distress.
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Aim 4 with related hypothesis. Examine the strength and direction of
relationships between scores on uncertainty, coping, and psychological distress within the
subtypes of MCI. This aim was addressed by calculating Pearson’s r or Spearman’s rho
as determined appropriate by the scatter plots calculated in aim 2 to investigate the
relationships between scores on uncertainty, coping, and psychological distress and the
subtypes of MCI. It was hypothesized that there will be no significant differences
between the subtypes of MCI in the strength and direction of uncertainty, coping, and
psychological distress.
Limitations

The limitations of this study are (1) recruitment from one academic-focused clinic
in the Midwest; (2) cross-sectional design; and (3) instrument limitations. Recruiting
subjects from one academic-focused clinic in the Midwest and cross-sectional design
limits generalizability of results. To address these concerns, further research is needed
with other populations within different care settings and areas of the US or other
countries. Specific to cross-sectional limitations, longitudinal studies will be needed to
evaluate if the study variables change over time. Finally, two instruments have not been
used in older adults with MCI (USS, SQ). It is possible that the psychometrics may be
different in older adults with MCI compared to older adults with other chronic illnesses.
Consequently, while this study may support the use of these instruments in older adults
with MCI, future studies will still be needed to support the psychometrics demonstrated
in this study.
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Treatment of human subjects

IRB approval was obtained from Froedtert Hospital / Medical College of
Wisconsin (FH/MCW) and Marquette University (MU) prior to the start of the study.
Both the IRB at FH/MCW and MU provided approval for the study, including
coordinated IRB form(s). Participants had the right to refuse participation, stop or
withdraw from the study at any point. Decisional ability of the participants was assessed
by their physician prior to consent (Simpson, 2010), and caregivers or other family
members were requested to be present with the participant if available during the consent
process to protect the rights of the participants. The caregivers and family members were
not invited to participate in the interview of the participant unless the participant
specifically requested that their caregiver or family member remain present for their
comfort. The benefits to participants for being in the study included potential emotional
benefits from discussing their experience, societal benefits from potential improvements
in care designed based on the information that they provide, and compensation with a $10
grocery store (Pick-n-Save) gift-card.
The risks posed to the participants included the potential for coercion, increased
stress, fatigue, or distress from the lengthy interview process or interview content, and the
potential loss of confidentiality. To prevent coercion, participants were recruited with the
aid of a flier and only a researcher not affiliated with the clinic discussed the study,
performed consent, and interviewed the participants. Additionally, to prevent potential
coercion from caregivers or family members, participants were asked again prior to the
start of the interview if they wished to proceed with the study and reminded of their right
to refuse participation and their right for their caregiver or family not to know of their
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refusal to participate. If participants decided to stop participating after consent,
caregivers or family members who were present at the consent were simply informed
(only if the researcher was asked) that it was decided that the participant was ineligible
for the study and nothing more. Participants were also reminded that staff at the clinic
would not be notified of their decision to participate in the study or not. To prevent
increased stress, fatigue, or distress, subjects were reminded periodically that they could
end the interview at any point and the researcher would end the interview if the
participant appeared to become upset. Finally, to address the potential loss of
confidentiality, several protection measures were in place including the use of numerical
identification rather than participant names on study papers, and password-protections on
files and hardware.
Vulnerable population. Older adults with either subset of MCI are considered
to be vulnerable, and at risk for coercion or mistreatment directly relating to their level of
impaired cognition, regardless of if the impairment is related to their memory. It is
important to clarify that cognition does not simply refer to one’s general knowledge or
IQ, and is not a stagnant process. Instead, cognition can broadly be defined as the skill to
organize thought and action towards obtaining goals (Miller & Wallis, 2009). To be able
to organize thought and action, abilities such as memory and judgment are needed. These
abilities are considered necessary for obtaining informed consent and subject to change
over time. Vulnerability related to impaired cognition is an important ethical concern for
clinicians, researchers, and institutional review boards, necessitating special protections
for involving older adults with MCI in research.
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The ethical concerns of research participant vulnerability and issues related to
informed consent from impaired cognition are not new concepts. Informed consent
processes and concerns in clinic and research settings for older adults with dementia have
been well explored (Simpson, 2010). However, the level of cognitive impairment seen
with dementia is greater than that with MCI (Petersen, 2003). Extra precautions or
cognitive testing taken for determining informed consent in older adults with dementia
may be inappropriate or excessive for older adults with MCI. Extra precautions or testing
could potentially result in a loss or violation of dignity or autonomy, confusion, or
emotional distress (Krohne, Slettebø, & Bergland, 2011). For researchers and clinicians,
inappropriate or excessive testing could also translate to increased time and expenses,
decreased retention or recruitment rates, or even impact study results through subjecting
participants to multiple tools or procedures.
In order to provide informed consent, a person must be able to demonstrate a
relatively high level of competence to ensure that their decision meets the ethical
requirements for informed consent. These requirements for informed consent are that the
decision is fully informed, voluntary, and given by a decisional person (Jefferson et al.,
2008; Mittal et al., 2007). With MCI, competence appears to be most affected in varying
degrees by deficits in abilities pertaining to memory, executive functioning, and
information processing (Jefferson et al., 2008; Okonkwo et al., 2007; Okonkwo et al.,
2008). Despite these deficits, MCI does not appear to greatly impact an older adult’s
ability to express choice.
Similar to determining the presence of MCI, the line at which someone
determines a person’s competence or capacity to give informed consent is not straight
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and clear cut (Grebe, 2008; Simpson, 2010). Including family members or significant
others on the informed consent process could be considered a loss of the participant’s
autonomy and a breach of confidentiality. Given the potential risks of coercion or loss of
autonomy or confidentiality, potential participants were recruited using a flier and asked
if they would like their caregiver present for the informed consent process and/or study.
In addition, all possible efforts were made to maintain participant confidentiality through
de-identifying and coding of the participant data.
Time frame

Months 1 - 11: Participant recruitment and data collection. Additional time
included in the estimate to account for potential problems with participant
recruitment/retention. Also during this time, the first manuscript (comparing the MoCA
to ACE-R) was prepared for publication.
Months 9 – 15: Continued and finalized participant recruitment and data
collection, performed preliminary data analysis and started drafting of the second
manuscript (study results).
Months 15 – 16: Submission of first and second manuscript for publication and
public dissertation defense.
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Abstract

Currently there is not a gold standard of screening for mild cognitive impairment (MCI).
The purpose of this study was to compare two cognitive screening tools for persons with
MCI: the Montreal Cognitive Assessment (MoCA) and revised Addenbrooke Cognitive
Exam (ACE-R).

The sample consisted of 50 older adults (>54 years old) diagnosed with MCI, who,
following a routine clinic appointment were administered the ACE-R and portions of the
MoCA not included on the ACE-R.

As expected, Pearson’s r indicated significant correlations between the instrument total
scores (r=0.80, p < 0.001). A majority of the instrument subscales indicated a high
degree of correlation, except the abstraction, fluency/naming, and language subscales.
Gender and diagnosis differences were identified with both instruments.

These findings suggest using the MoCA for cognitive screening in primary care settings
may be more sensitive for MCI with fewer items than and a high degree of consistency
with the ACE-R.
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Mild cognitive impairment (MCI) is becoming an increasing concern as a
potential pre-dementia condition, making it a new target for early diagnosis and
interventions to maintain quality of life through slowing or preventing the progression to
dementia. From major population-based studies, the recently reported average
prevalence of MCI in older adults is 18.9% (Petersen et al., 2014). MCI is generally
diagnosed starting around the age 60 years and is defined as functional impairment
affecting mental processes, such as memory or executive functioning, that is more than
what is expected for normal aging and often precedes dementia (Petersen, 2003; Petersen,
2011). Diagnostically MCI can further be broken down into two subsets: Amnestic
versus non-amnestic MCI (Petersen, 2011). The main difference between these subsets is
the presence of memory impairment (amnestic or aMCI) or lack of significant memory
impairment (non-amnestic or naMCI). However, despite fundamental differences
between aMCI and naMCI, there is a significant lack of evidence for screening or treating
one subset differently from the other (Lin, Vance, Gleason, & Heidrich, 2012).
In general, the diagnosis of MCI typically starts with the patients’ or family
members’ observation of changes in the individual’s cognition such as forgetting things
or trouble with job performance (Albert et al., 2011; Petersen, 2011; Portet et al., 2006).
These observations are accompanied by declines in cognitive functioning greater than 1.5
standard deviations of what is normally expected for age on a brief cognitive screening
instrument. A variety of instruments that assess cognitive functioning are commonly
administered in a primary care setting to indicate if further cognitive functioning testing
is warranted. Further testing beyond the primary care setting consists of comprehensive
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neuropsychological testing in combination with the health practitioner’s assessment to
assign the diagnosis of MCI (Smith & Bondi, 2013).
Presently there is no gold-standard instrument for screening for MCI in primary
care settings. Historically, the majority of instruments used to screen for MCI were
originally developed to screen for dementia and not the more subtle cognitive changes
that accompany MCI (Smith & Bondi, 2013). Many of these screening instruments for
dementia lack sensitivity and are unable detect signs of MCI. Thus, persons with MCI
are likely to be incorrectly screened as normal rather than MCI using such instruments.
For example, Nasreddine and colleagues have demonstrated that the Mini-Mental State
Examination [MMSE] can accurately identify dementia but is less specific in identifying
MCI (Nasreddine et al., 2005). This has led to the creation of number of instruments
designed to detect MCI. Such instruments include but are not limited to the Montreal
Cognitive Assessment [MoCA] (Nasreddine et al., 2005) and Addenbrooke’s Cognitive
Exam revised [ACE-R] (Mioshi, Dawson, Mitchell, Arnold, & Hodges, 2006). The
MoCA and ACE-R have some similar items to the MMSE but have more items which
test higher levels of cognitive functioning such as abstraction, language, and fluency.
Thus, a need exists to identify an instrument that accurately detects MCI in the primary
care setting.
Purpose

The purpose of this study was to compare two commonly used instruments for the
screening of MCI in older adults (MoCA and the ACE-R), in order to provide evidence
for which instrument might be more appropriate for use in a primary care setting. This
purpose will be addressed through evaluating 3 research questions:
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1.

What is the internal consistency and correlation of total and subscale scores
between the MoCA and ACE-R in a sample of older adults with MCI?

2.

To what degree do the MoCA and ACE-R accurately identify older adults with
MCI?

3.

Are there any differences or relationships in total and subscale scores on the
MoCA and ACE-R by demographic variables such as age, gender, and diagnosis
subtype: aMCI vs. naMCI?
Methods

This cross-sectional study recruited a convenience sample of 50 older adults
diagnosed with MCI from an out-patient neurology clinic at an academic medical center
over a 5 month period while they attended routine follow-up appointments. Informed
consent was obtained from all subjects and their care-partners as part of this institutional
review board-approved study. Subjects were included in this study if they were over the
age of 54 years old, had a diagnosis of MCI supported by neuropsychological testing and
neurologist assessment, and could speak/write in English. Subjects were excluded if they
did not meet the above inclusion criteria or if their neurologist documented in the patient
record that a neuropsychiatric disorder(s) might be complicating their diagnosis of MCI.
As part of their clinical care, all subjects completed the ACE-R during their
scheduled clinic appointment. Following the appointment, subjects were invited to
participate by clinic staff and the study PI performed informed consent then administered
a brief demographic questionnaire followed by the MoCA excluding portions which were
repetitive of items in the ACE-R (which were then rescored from the ACE-R for a total
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MoCA score). The items which were excluded from the MoCA included: (1) Cube copy,
(2) clock draw, (3) serial 7’s, and (4) orientation (date, month, year, etc.).
Instruments

Montreal Cognitive Assessment (MoCA). The MoCA was first presented in
2003 as one of the few available instruments specifically developed to screen for MCI
(Nasreddine, 2011; Nasreddine et al., 2005). The target population for the MoCA is
patients who present with “mild” cognitive complaints who might perform within the
normal range on the MMSE (Nasreddine et al., 2005). The first draft of the MoCA
assessed 10 different cognitive domains, but was later limited to 8 domains (11-items, 30points) after it was concluded that 5 items did not discriminate well between MCI,
dementia, and healthy controls (Nasreddine et al., 2005). The 8 domains addressed in the
final version include: Short term memory, visuospatial abilities, executive functioning,
attention, concentration, working memory, language, and orientation. Lower scores
indicate higher levels of cognitive impairment. The MoCA exhibits acceptable internal
consistency (Cronbach’s alpha = .83) (Nasreddine et al., 2005).
Addenbrooke’s Cognitive Assessment, revised edition (ACE-R). Unlike the
MoCA, the ACE-R was not developed to screen solely for MCI but instead to screen for
the early stages of dementia (including MCI) and differentiate between the many
subtypes of dementia (Mioshi et al., 2006). The ACE-R contains 26 item components
(over double the number of items on the MoCA) which can be combined to produce 5
subscales and produce the total score out of 100 points: (1) Attention/Orientation (18
points), (2) Memory (26 points), (3) Fluency (14 points), (4) Language (26 points), and
(5) Visuospatial (16 points) (Mioshi et al., 2006). Again, lower scores equate to higher
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levels of cognitive impairment. Similar to the MoCA, the ACE-R exhibits acceptable
internal consistency (Cronbach’s alpha= .80) (Mioshi et al., 2006).
Data analyses

Data analyses were performed using SPSS statistical software. To describe
participants in the study, frequencies and group differences on baseline demographics
were examined using one-way analysis of variance or χ² tests where applicable. For
research question one, total and subscale ranges were calculated for both instruments. In
addition, bivariate correlations were calculated between the total and subscale scores on
the two instruments. Cronbach's alpha was used to assess the internal consistency of both
instruments. Research question two was addressed by comparing the percentage of
participants identified as exhibiting normal cognition (false negative) rather than MCI in
both instruments. The threshold score for MCI was previously identified by the
instrument authors as 88 for the total ACE-R and 26 for the total MoCA score. Finally,
for research question three, group differences between scores with regard to demographic
variables (gender, and diagnosis) were assessed using t-tests and the relationship between
scores and age was evaluated using bivariate correlation.
Results

A total of 50 people were recruited for the study with an average age of 75.88
(SD=7.80). The sample was largely Caucasian (98.0%) and highly educated with at least
98.0% having some college education. The sample included a similar number of males
and females with either an aMCI (males n= 18, females n=10) or naMCI (males n=14,
females n=8) diagnoses (χ²(1)=0.002, p=0.96). There was also no significant difference
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(t(48)=1.01, p=0.32) in the mean age of participants by gender (male mean age=76.72,
females mean age=74.39). However, there was a significant difference in mean age by
diagnosis (t(48)=2.56, p=0.01) with aMCI subjects being older (mean age=78.25) than
those with naMCI (mean age=72.86). 54.0% of subjects had their MCI diagnosis for less
than one year, and there were no significant differences in the length of diagnosis by
gender (χ²(5)=4.73, p=0.45) or diagnosis (χ²(5)=3.60, p=0.61).
Research question 1: What is the internal consistency and correlation of total and
subscale scores between the MoCA and ACE-R in a sample of older adults with
MCI?

Score distributions on the ACE-R and MoCA appear in table 1. As expected, the
mean total score for both scales indicated the sample exhibited MCI with mean scores
less than the threshold scores 88 (ACE-R) and 26 (MoCA). Internal consistency of both
instruments was somewhat lower than expected (α~0.60), which may be related to sample
homogeneity (Bernardi, 1994). For research question one, bivariate correlations were
assessed on the total scales and subscale scores of the MoCA and ACE-R (table 2).
While the total scores of the ACE-R and MoCA were significantly positively correlated
(r=0.80, p<0.001), the instrument subscales did not all positively correlate. Specifically,
the abstraction and language subscales from the MoCA did not correlate with any of the
ACE-R subscales.
Research question 2: To what degree do the MoCA and ACE-R accurately identify
older adults with MCI?

For research question two, scores on the ACE-R and MoCA were examined using
cut off scores of 88 (ACE-R) and 26 (MoCA) to determine the percentage of subjects
who screened positive for cognitive impairment (figure 1). Of the 50 subjects, 20% (n =
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10) screened within normal range on either one (MoCA n=2, ACE-R n=5) or both
instruments (n=3). Of those, 90% were male, and 100% were college educated. The
resulting sensitivity was 90.00% for the MoCA and 84.00% for the ACE-R. Specificity
was not calculated as the study only included older adults with a diagnosis of MCI.
Research question 3: Are there any differences or relationships in total and subscale
scores on the MoCA and ACE-R by demographic variables such as age, gender, and
subtype of MCI?

Finally, to address research question three, total and subscale scores on the ACER and MoCA were compared by subject gender, MCI subtype, and age. The bivariate
correlation indicated there was no significant relationship between scores and age.
However, the t-tests demonstrated significant group differences in scores by MCI subtype
and diagnosis (table 3). Males scored significantly higher than females on both
instruments (indicating less impairment). Males scored significantly better than females
(p=0.003-0.04) on the visuospatial (MD=1.99) and memory (MD=2.43) subscales of the
ACE-R and the visuospatial (MD=1.00) and attention (MD=0.83) subscales of the
MoCA. In addition, subjects with aMCI scored significantly lower than those with
naMCI on both instruments (indicating more impairment). Subjects with aMCI scored
lower than those with naMCI (p=0.004-0.04) on the attention/orientation (MD=-0.76) and
memory (MD=-2.67) subscales of the ACE-R, and the orientation (MD=-0.21) and
abstraction (MD=-0.63) subscales of the MoCA.
Discussion

The purpose of the study was to compare two commonly used instruments for the
screening of MCI in older adults (MoCA and the ACE-R), in order to provide evidence
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for which instrument might be more appropriate for use in a primary care setting. The
results indicated that the ACE-R and MoCA are highly correlated (with the exception of a
few subscales) with both instruments exhibiting a high degree of sensitivity for detecting
MCI in older adults. The internal consistency of both instruments was lower than
expected for both instruments which could be attributed to homogeneity of the relatively
small sample (Bernardi, 1994). These findings must be considered within the framework
of previous studies, clinical implications, instrument bias, and limitations of the study’s
design.
There have been two other studies which compared the ACE-R and MoCA
directly, neither of which has reported differences in the instruments by diagnosis or
gender. In one pilot study, the ACE-R and MoCA were compared with a very small
sample of 15 persons with MCI versus 20 healthy controls (Ahmed et al., 2011). The
results reported sensitivity and specificity for both instruments was 90% and 67%
(respectively), using a cut off score of 88.5 for the ACE-R and 23.5 for the MoCA (as
opposed to the recommended score of 26) (Ahmed et al., 2011). Researchers used a cut
off of 23.5 as it was found to discriminate between controls and MCI in their sample
(Ahmed et al., 2011). If the cut off score of 23.5 for the MoCA was used in this study,
the sensitivity of the instrument would have dropped to 62.00%, supporting the need to
use the instrument author’s recommended cut off of 26 (Nasreddine et al., 2005).
Another study compared the two instruments in 91 patients with MCI greater than
or equal to one year after a stroke or transient ischemic attack (Pendlebury, Mariz, Bull,
Mehta, & Rothwell, 2012). Similar to the results of this study, total MoCA and ACE-R
scores were significantly, positively correlated (Spearman r2=0.76). Using a cut off score
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of 26, the sensitivity and specificity of the MoCA were reported as 87% and 63%
respectively. For the ACE-R, a cut off of 88 resulted in sensitivity and specificity rates of
56% and 100% respectively. The resulting sensitivity for the ACE-R was significantly
different from this study (84%), but can likely be attributed to differences in sampling
where Pendelbury and colleagues (2012) used participants whose MCI may be related to
prior transient ischemic attacks or stroke.
Clinical implications

Both instruments have been validated in several languages and adapted cultural
differences (Mioshi et al., 2006; Nasreddine, 2011; Nasreddine et al., 2005). Both
contain some identical items: (1) cube copy, (2) naming animals, (3) serial 7 subtraction,
and (4) orientation questions. However, while both instruments contain similar items
(and similar subscales), there are some notable differences between the instrument
subscales. For example, the MoCA contains the subscale “abstraction” which contains
two items asking the participant to identify how two things are similar (e.g. banana and
orange). The ACE-R does not contain an abstraction scale and does not have any similar
items. In addition, the abstraction subscale from the MoCA was not correlated with any
of the ACE-R subscales. Lack of significant correlations between the subscales suggests
that the scales may not be measuring the same things. Clinically, abstraction is a higher
form of cognitive functioning which is necessary for performing daily tasks and can be
predictive of behavior such as medication adherence (Insel, Morrow, Brewer, &
Figueredo, 2006; Jeste et al., 2003) and glycemic control in older adults with diabetes
(Amer et al., 2014). The MoCA may be useful for identifying older adults in need of
medication management interventions, however further research is needed.
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Although the visuospatial subscales of the ACE-R and MoCA were significantly
correlated (r=0.67, p<0.001), the relationship is likely attributed to both instruments
containing the cube copy and clock draw tasks. It is important to note that the ACE-R,
unlike the MoCA, does not contain a trail-making or similar type of task. Trail-making
tasks, specifically Trails B, are indicative of executive functioning (Sánchez-Cubillo et
al., 2009), which is commonly impaired in persons with naMCI and necessary for
complex tasks such as medication adherence (Insel et al., 2006) and driving (Richardson
& Marottoli, 2003). Performance on trail-making tasks might aid practitioners in
deciding what patients need to be referred for driving evaluations. The MoCA contains
Trails B, making it more useful for primary care practitioners for the quick evaluation of
executive functioning.
Finally, while the ACE-R and MoCA both contain the item “tell me all of the
words that you can think of that begin with the letter p [ACE-R] or f [MoCA]” the
subscales which contain the item were not correlated. There are several reasons why there
may be no relationship between the subscales: (1) Test fatigue, (2) Other questions within
the subscales could be measuring different things, (3) Item order could possible cause
more perseveration in one test than the other, and (4) Broader differences between the
letter (p or f) in the item, e.g. participants having an easier time naming p words than f
words.
Instrument bias?

The differences between genders and diagnoses on the ACE-R and MoCA scores
noted in this study raise questions of possible instrument bias. With regard to gender,
differences in performance could potentially be related to participants’ educational
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background and/or employment (e.g. more men than women employed in technical
backgrounds necessitating the use of visuospatial skills more often), which were not
widely explored in this study. In addition, gender differences on the instruments may be
related to broader differences in brain anatomy, function, or chemistry between genders
(Cahill, 2006). Differences in performance by diagnosis on the other hand are likely
mostly related to memory tasks being weighted more heavily than other tasks in the total
instrument scores or study limitations.
Limitations

The relationship of educational level to score on the ACE-R and MoCA could not
be fully assessed in this study given the highly educated, homogeneous sample. Both
instruments are affected by educational level, despite not being measures of general
knowledge or IQ (Nasreddine et al., 2005). Consequently, the educational background of
participants should be accounted for in any evaluation of instruments of cognitive
functioning. However, educational level is only taken into account in scoring on the
MoCA: those at a high school education or below receive one extra point.
Alike many previous studies on MCI, collecting data from only one clinic resulted
in a very homogeneous sample which limits the generalizability of these results. In
addition, the focus of the clinic is “memory disorders,” consequently; results may not be
applicable to the other populations where the MoCA has been used (such as persons with
cardiovascular disease, stroke, or Parkinson’s disease). Potentially impacting reliability,
different test administrators (clinic staff vs. PI), the timing between instruments, and
altered timing between questions on the MoCA through omission of repeated questions
may have affected study results.
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Finally, internal consistency (Cronbach’s alpha) was surprisingly low in this study
and may not be the best way to evaluate the reliability of cognitive examinations with this
small, homogenous sample (n=50).

igher Cronbach’s alphas have been reported in

other literature with larger and more diverse samples ranging around 0.84 to 0.83 for both
instruments (Fujiwara et al., 2010; Mioshi et al, 2006; Nasreddine et al., 2005; Rahman &
Gaafary, 2009).
Recommendations for future research

Since the conclusion of this study, a new edition of the ACE-R (the ACE-III) has
been published and has been validated in older adults with Alzheimer’s disease and
frontotemporal dementia (Hsieh et al., 2013). However, it is important to note that the
ACE-III also does not contain items pertaining to abstraction or trail-making. Future
studies will be needed to determine the reliability and validity of the ACE-III in
comparison to the MoCA for the screening of MCI. Additionally, larger and more
diverse sample sizes are needed to consider exploratory or confirmatory factor analysis to
further assess the structure of each instruments’ subscales (Pawlowski, Segabinazi,
Wagner, & Bandeira, 2013). Finally, further studies are also needed to determine if
group differences between aMCI vs. naMCI on the abstraction subscale of the MoCA are
consistent. Such studies could support the clinical use of the MoCA for targeting older
adults at risk for problems such as medication noncompliance or glycemic control issues.
Conclusions

The MoCA includes fewer items and requires less time to complete in comparison
to the ACE-R. Both instruments appear to be reliable and valid for the screening of MCI
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in a well educated sample. However, the recommendation of this study is to use the
MoCA as a brief screening instrument for MCI for three reasons. (1) The MoCA is
shorter than the ACE-R, which is an important consideration for primary care settings or
other areas where assessment time may be limited or where subjects may be at risk for
instrument fatigue. (2) The MoCA was slightly more sensitive than the ACE-R for
detecting MCI in this sample. And (3) the MoCA contains a trail-making task and an
abstraction subscale on which aMCI vs. naMCI subjects scored differently. Although
future research is needed, the abstraction subscale may help clinicians to identify patients
at risk for medication non-compliance or glycemic control issues.
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Tables and figures

Table 1
Instrument psychometrics

Variable

M

SD

Range

α

ACE-R

80.02

7.58

57 - 94

0.68

MoCA

22.10

3.00

14 - 28

0.64

Table 2
Correlations between instrument totals and subscales

MoCA
Total

Attention

Orientation

Delayed
Recall

Abstractio

Naming

Language

Visuospati

n

al

Total

.80**

.46**

.54**

.45**

.18

.27

.08

.52**

Attention-

.53**

.29**

.70**

.28*

.02

.36*

.05

.10

Memory

.56**

.25

.43**

.57**

.10

.32*

-.14

.21

Fluency

.26

.10

.13

-.09

.06

-.01

.26

.34*

Language

.46**

.15

.26

.28

.26

.26

.11

.24

Visuospatia

.57**

.55**

.18

.14

.11

-.13

.11

.67**

A
C Orientation
E
R
l

Note. Shaded areas represent subscales that should measure similar constructs.
*p<0.05, **p<0.001
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Table 3.
Significant differences in ACE-R and MoCA scores by demographic variables

Variable

Instrument

t

df

p

MD

Male vs.
Female

ACE-R

3.29

48

0.002

6.72

MoCA

2.46

48

0.018

2.07

ACE-R

-2.29

48

0.030

-4.75

MoCA

-2.15

48

0.040

-1.77

aMCI vs.
naMCI

90%
Positive
Negative
84%

Figure 1. Percentage of subjects screening positive or negative for cognitive impairment.
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Abstract

A diagnosis of mild cognitive impairment (MCI) can result in uncertainty, dysfunctional
coping, and psychological distress; all potentially influenced by time and level of
cognitive impairment. A conceptual framework that addresses these consequences of
MCI could guide the development of nursing interventions. However, such a framework
does not currently exist. The primary aim of this study was to test components of
Sjostedt’s conceptual framework for MCI by examining the relationships among
uncertainty, coping, psychological distress, time since diagnosis, and level of cognitive
impairment from MCI. A cross-sectional design was used with surveys completed by 91
older adults receiving care for MCI at a neurology clinic. Participants reported low to
moderate levels of uncertainty and psychological distress, and often used emotionfocused coping strategies. However, 25.27% of the sample reported moderate/severe
psychological distress. Significant relationships (p<0.05) were found between
uncertainty, coping, and psychological distress, providing support for the proposed
conceptual framework.
Keywords: Mild cognitive impairment, uncertainty, coping, and psychological distress
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Mild cognitive impairment (MCI) is considered a cognitive stage between normal
functioning and dementia. MCI usually affects older adults starting around 60 years of
age with an average prevalence of 18.9% (Petersen, 2003; Petersen, 2011; Petersen et al.,
2014). Older adults with MCI report higher rates of indirect care use, such as informal
assistance with activities of daily living, and annual direct medical costs (approximately
$808-3,530 more per year) compared to those without MCI (Leibson et al., 2012; Luppa
et al., 2008; Zhu et al., 2013). MCI can be broken down into two main subtypes that
include amnestic (aMCI) featuring predominately deficits in memory or nonamnestic
(naMCI) with deficits outside of memory, such as executive functions, visuospatial
ability or language (Petersen et al., 2014). Despite fundamental differences between
aMCI and naMCI, there is a significant lack of evidence for treating or screening one
subset differently from the other (Gauthier & Touchon, 2005; Lin, Vance, Gleason, &
Heidrich, 2012). Both subtypes of MCI result in challenges from cognitive alterations
and uncertainty that can contribute to psychological distress, resulting in anxiety, social
withdrawal, anger, relationship disturbances, or depression (Banningh, Vernooij-Dassen,
Rikkert, & Teunisse, 2008; Blieszner, Roberto, Wilcox, Barham, & Winston, 2007;
Lyketsos et al., 2002; Petersen et al., 2014). Effective coping with MCI might help to
decrease uncertainty and psychological distress; but the relationships between coping,
uncertainty, and psychological distress have not been explored in older adults with MCI.
Nurses are in a unique position to provide interventions to older adults to promote
understanding and to help them overcome challenges associated with MCI (Lin et al.,
2012). A framework to assist in addressing the consequences of MCI, specifically one
that examines the relationships among MCI diagnosis, uncertainty, coping and
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psychological distress, is essential to guide the development of nursing interventions that
might help older adults with MCI cope effectively.
A conceptual framework for MCI

Diagnostic criteria for MCI and a theoretical progression of cognition from
normal aging to dementia provide some justification for research and practice, but do not
provide sufficient guidance for nursing interventions that might help older adults with
MCI and their families cope. In addition, while the theoretical progression suggests that
cognition will worsen over time, the path and speed of the progression is often uncertain;
older adults with MCI transition along the continuum at differing and unpredictable rates
where their cognition may improve, remain stagnant within the range of MCI, or progress
to dementia (Banningh et al., 2008; Gauthier & Touchon, 2005; Lingler et al., 2006;
Werner & Korczyn, 2008). Other theories that discuss coping with chronic illnesses, do
not account for this sometimes unpredictable MCI trajectory on the older adult’s ability
to appreciate the appraisal of their situation or psychological distress. Consequently, a
framework that addresses the relationships of antecedents and consequences of MCI is
imperative to improve the nursing care for these older adults.
Development a framework

The lack of a specific theoretical framework describing the antecedents and
consequences of MCI and limitations of existing frameworks related to other chronic
illnesses necessitated the new conceptualization of MCI to provide support for research
and the development of interventions specific for older adults with MCI. The Sjostedt
framework for older adults with MCI (Figure 1) encompasses both aMCI and naMCI and
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was developed to meet this need using concept analysis methods proposed by Rogers
(Rodgers & Knafl, 2000). This framework evolved from a literature search that
encompassed years 2000 to 2014 using the CINAHL, Google-scholar, Web-of-Science,
Proquest dissertations, and PubMed databases, followed by ancestral searches of articles
obtained. Search terms included “mild cognitive impairment,” and surrogate terms for
MCI combined with terms such as: older adults, geriatrics, chemotherapy, alcohol,
nursing, perception and concept.
Sjostedt framework for MCI

In the Sjostedt framework, MCI is defined as an unstable state of limbo weighted
by heterogeneity between older adults’ normal and abnormal continuums (normal aging
versus dementia). Figure 1 illustrates the antecedents, attributes, and consequences of
MCI proposed within the framework. The main consequence of MCI is uncertainty,
which then leads to the other consequences of coping and psychological distress.
Uncertainty from MCI stems mainly from inconsistencies in MCI diagnosis and
variability in MCI trajectories (Bensadon & Odenheimer, 2013; Dean & Wilcock, 2012;
Lu, Haase, & Farran, 2007; Werner & Korczyn, 2008; Yanhong, Chandra, & Venkatesh,
2013). Uncertainty can influence how older adults respond and relate to any illness,
treatments, or hospitalizations (Landis, 1996), thus potentially influencing the coping and
psychological distress which result from MCI (Banningh et al., 2008; Blieszner et al.,
2007; Lingler et al., 2006; Lu et al., 2007). Guided by the Uncertainty in Illness Theory
(Mishel, 1988) or other modifications or proposed frameworks influenced by it,
uncertainty has been quantitatively explored in chronic conditions such as cancer
(Agretelis, 1999; Kazer, Bailey, Sanda, Colbery, & Kelly, 2011; Lien, Lin, Kuo, & Chen,
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2009; Sammarco & Konecny, 2010), Parkinson’s disease (Sanders-Dewey, Mullins, &
Chaney, 2001), and fibromyalgia (Anema, Johnson, Zeller, Fogg, & Zetterlund, 2009;
Reich et al.; 2006). The Uncertainty in Illness Theory’s assumptions regarding the
stimulus frame and appraisal do not account for the potential impact of MCI and lack of
awareness of deficits in older adults with MCI; this limits the theory’s applicability. In
addition, uncertainty has not been quantitatively addressed in older adults with MCI.
The Sjostedt framework hypothesizes that coping and psychological distress from
MCI result as responses to the diagnosis and symptoms related to MCI. Findings from
one study suggest that some older adults with MCI might use avoidance oriented (or
dysfunctional) coping through attempts to improve memory performance, avoidance of
activities to keep from making mistakes or masking of deficits (Banningh et al., 2008).
Yet, findings from other studies have indicated that older adults with MCI might also use
emotion-focused or problem-focused coping through methods such as positive reframing,
acceptance, religion, planning, and instrumental support (Lin & Heidrich, 2012;
McIlvane, Popa, Robinson, Houseweart, & Haley, 2008). Emotional-focused and
dysfunctional coping might increase psychological distress whereas problem-focused
coping might reduce psychological distress, similar to the relationships demonstrated
within other chronic illnesses (Barron, 2000; Lauver, Kruse, & Baggot, 1999; Lynch,
Kroencke, & Denney, 2001; Sanders-Dewey et al., 2001).
Psychological distress from MCI may present as anger, depression, anxiety,
somatic symptoms, sadness, frustration, loss of self-confidence, discouragement,
loneliness, rejection, inactivity, shame, self-blame, helplessness or loss of control
(Banningh et al., 2008; Blieszner et al., 2007; Carpenter et al., 2008; Dean & Wilcock,
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2012; Ellison, 2008; Lu et al., 2007). One study found that older adults with MCI were
unable to identify any positive consequences related to the condition (Banningh et al.,
2008). Yet, other studies have found more positive emotions, such as happiness or relief
that it is not dementia, satisfaction from professional validation of their cognitive
symptoms, optimism, and comfort by being able to reduce uncertainty in naming their
cognitive symptoms (Dean & Wilcock, 2012; Lingler et al, 2006; McIlvane et al., 2008).
Based upon the literature, MCI is a diagnosable and valid chronic condition that
does not cause physical pain or result in death. As a chronic condition, it is expected that
the relationships demonstrated between uncertainty, coping, and psychological distress in
older adults with MCI may be similar to what has been observed among older adults with
other types of chronic conditions. Finally, consistent with current recommendations for
care (Lin et al., 2012), this study also assumes that while the subtypes of MCI may be
fundamentally different, nursing care related to MCI will not vary greatly based upon the
subtype of MCI.
Purpose

This study is unique in quantitatively addressing consequences of MCI and is
foundational in validating aspects of a conceptual framework that can guide the
development of nursing interventions and further research for older adults with MCI.
The primary purpose of this study was to test select components of a new conceptual
framework for MCI by examining the relationships among uncertainty, coping,
psychological distress, time since diagnosis, and level of cognitive impairment from
MCI. Secondary aims were to: (a) to describe the levels of uncertainty, coping, and
psychological distress in older adults with MCI; (b) examine the differences in scores on
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uncertainty, coping, and psychological distress between the two subtypes of MCI; and (c)
examine the strength and direction of relationships between scores on uncertainty,
coping, and psychological distress within the subtypes of MCI.
The hypotheses generated from the proposed framework that will be tested in this
study are: (a) there will be a significant negative relationship between time since
diagnosis and level of cognitive impairment from MCI, where longer time since
diagnosis will be associated with lower scores of cognition; (b) there will be significant
positive relationships between uncertainty and use of coping strategies (emotion focused,
problem focused, or dysfunctional coping); (c) there will be significant positive
relationships between uncertainty and psychological distress; (d) there will be significant
positive or negative relationships between use of coping strategies and psychological
distress; (e) the relationships between level of cognitive impairment from MCI and use of
coping strategies will be mediated by uncertainty; (f) the relationships between level of
cognitive impairment from MCI and psychological distress will be mediated by
uncertainty and coping; and (g) there will be no significant differences between the
subtypes of MCI in the strength and association of uncertainty, coping, and psychological
distress.
Methods

Prior to approaching any subjects, institutional review board approval for the
study was obtained from the study site. The study design used was descriptive, crosssectional, and correlational. A convenience sample of 91 older adults was recruited from
an outpatient neurology clinic. Subjects were included if they were over 54 years of age,
had been given a diagnosis of MCI by their attending physician supported with

112
neuropsychological testing, and could understand and speak English. Participants were
excluded if they did not meet the above inclusion criteria, if their physician suspected that
other neuropsychiatric disorders or chronic conditions might be complicating or masking
their diagnosis of MCI, or if they had progressed to dementia. Analyses for aim 1
necessitated the largest sample, hence aim 1 was used to guide the sample size
estimation. Sample size was estimated using a method from Cohen & Cohen (1983),
resulting in estimating a sample of 91 older adults to yield a power of 0.80 at α = 0.05.
Participant recruitment occurred over the course of 62 consecutive weeks
(excluding federal-holidays or weeks when the clinic was not operational) starting in July
2013. Potential participants were identified prior to their scheduled appointment in the
neurology clinic by clinic staff. After completing their scheduled appointment, all
potential participants were invited to participate in the study that same day. Consent and
data collection then occurred as an in person interview with the study PI (unaffiliated
with the clinic) in an available exam room at that clinic.
Instruments

All instruments in this study were selected to be consistent with the conceptual
definitions of the variables, and their reliability and validity (see table 1). Instruments to
assess the variables by order of administration were: Montreal Cognitive Assessment
(lower scores equate to a higher level of cognitive impairment from MCI) (Nasreddine,
2011), a Demographic Survey, Uncertainty Stress Scale (higher scores indicate more
uncertainty) (Hilton, 1996), Brief COPE (higher scores indicate more use of that coping
strategy) (Carver, 1997), and Kellner Symptom Questionnaire (higher scores indicate
more psychological distress) (Kellner, 1987). The demographic survey measured time
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since initial MCI diagnosis in months and years, and select antecedents which could
potentially have an effect on uncertainty, coping, and psychological distress: subject
gender, age, race/ethnicity, educational level, marital status, religious affiliation, and
socioeconomic status. The demographic survey was administered as part of the in person
interview; however, time since initial MCI diagnosis was obtained from participants’
electronic medical records after completing the in person interview.
Data analysis

Data analysis was performed using SPSS statistical software version 21.0 (IBM
Corp, 2012). All data were assessed for frequencies, mean, median, mode, outliers
(scatter plots), skewness and kurtosis. Prior to conducting data analysis to meet the study
aims, differences related to demographic variables (i.e. gender) on the other variables of
level of cognitive impairment from MCI, subtypes of MCI, time since initial diagnosis
with MCI, uncertainty, coping, and psychological distress were examined using one-way
analysis of variance (ANOVA) or χ² tests as appropriate. Any differences related to
demographic variables were considered as possible confounding variables within the
remaining analyses to meet study aims. Descriptive statistics were then calculated for
each study instrument and assessed for group differences between MCI subtypes or other
descriptive variables using t-tests and ANOVA. To evaluate the primary study purpose
and associated hypotheses, first bivariate correlations were calculated to determine the
relationship of study variables and continuous descriptive variables. Next hierarchical
multivariate regression analyses were conducted with each psychological distress
subscale as separate dependent variables. Differences in the strength or direction of study
variables by MCI subtype were assessed using methods for determining the region of

114
significance in multiple linear regression 2-way interactions (Preacher, Curran, & Bauer,
2006); and Sobel tests were calculated to assess for potential mediating effects in the
models (Preacher & Leonardelli, 2001).
Results

A total of 91 older adults were recruited for the study with a mean age of 75.22
(SD = 0.49, range 58-89 years). Participants were primarily Caucasian (94.5%),
Christian (87.91%), married (76.9%), retired (85.7%) and had an average of 15.37 years
of education (SD=3.52, range 4-27 years). The mean employment duration was 28.21
years (SD = 13.85, range 2-60 years) with professions split between office/law/sales
(49.5%), health/education/service (27.5%), and engineering/manual (23.1%). The sample
contained a relatively even split of aMCI (57.14%) and naMCI (42.86%) diagnoses, and
participants had a mean MCI duration of 2.36 years (SD = 2.29, range <1-10 years).
There were no significant differences (p ≤ 0.05) between aMCI vs. naMCI subtypes on
any of the demographic variables.
Table 2 describes the participants’ responses on each of the study instruments by
order of administration with group differences noted between the MCI subtypes. The
only demographic group difference on study instrument means was with marital status;
older adults who were divorced (n=6) reported significantly higher rates of depression,
SQ-D (F(4, 86) = 2.85, p = 0.03), compared to those who were married (MD = 5.52).
Bivariate correlation revealed only a few relationships between the continuous
demographic variables and study instruments. Age was significantly negatively
correlated with scores on the MoCA (r = -0.23, p = 0.03), emotion focused coping (r = 0.45. p < 0.001), problem focused coping (r = -0.47, p < 0.001), dysfunctional coping (r =
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-0.34, p = 0.001), and anxiety (r = -0.26, p = 0.01). In addition, MCI duration was
significantly positively correlated with somatic symptoms (r = 0.35. p = 0.001).
Participants indicated the least uncertainty (USS-U) and stress from uncertainty
(USS-S) about whether they are being told the truth regarding their cognitive impairment
(USS-U M = 0.51 ± 1.11; USS-S M = 0.33 ± 0.63) and if they will be well cared for by
the nurses (USS-U M = 0.57 ± 1.17; USS-S M = 0.24 ± 0.67) or other hospital staff
(USS-U M = 0.59 ± 1.12; USS-S M = 0.27 ± 0.56). Participants indicated the most
uncertainty and stress about whether their MCI will be the same in 5 years (USS-U M =
1.65 ± 1.42, USS-S M = 0.87 ± 0.79), if their MCI will interfere with their ability to do
their usual activities (USS-U M = 1.49 ± 1.41, USS-S M = 0.76 ± 0.81), and the stability
of their MCI (USS-U M 1.43 ± 1.10, USS-S M = 0.78 ± 0.70). Close to half of the
sample (42%) indicated that they had no positive feelings, such as hope or optimism,
about uncertainty from MCI. However, there were no significant differences between
those who reported positive feelings vs. those who did not on the subscales of the USS,
MoCA, Brief COPE, and Symptom Questionnaire or by subtype of MCI (p = 0.08 –
0.77).
Table 3 illustrates the bivariate correlations between the USS-U, USS-S, and
other study variables. A strong significant positive correlation was noted between the
USS-U and USS-S, indicating that the subscales likely measure the same concepts. In
addition, when completing the instruments, some participants made comments about
equating uncertainty with worry or stress accompanied by circling their response on the
USS-U items to indicate that worry or stress rather than uncertainty. Consequently, only
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the USS-S was considered as a variable for uncertainty within the testing of the
conceptual framework.
The mean of average responses on the Brief Cope indicated that participants
reported significantly higher (p < 0.001) use of emotion focused coping strategies (M =
1.23 ± 0.69) and problem focused strategies (M = 1.11 ± 0.82) in comparison to
dysfunctional coping (M = 0.48 ± 0.41). The most frequently reported strategies fell
within the emotion focused coping subscale and were acceptance (M = 1.81 ± 0.90), use
of emotional support (M = 1.42 ± 0.94), and religion (M = 1.36 ± 1.14).
Mean responses on the psychological distress subscales (table 2) fell within the
“normal range” for depression (≤ 6), anxiety (≤ 7), anger/hostility (≤ 8), and somatic
symptoms (≤ 8) (Kellner, 1987).

owever, it is important to note that almost a quarter of

the sample fell within the moderate to severe range for depression (20.88%), anxiety
(25.27%), or somatic symptoms (21.98%). In addition, 9.89% of participants fell within
the moderate to severe range for anger/hostility. Although a higher proportion of
participants with naMCI versus aMCI scored within the moderate to severe range, a
significant difference between the subtypes only existed for somatic symptoms (χ2(2) =
5.98, p = 0.05). Of participants with naMCI, 30.77% reported moderate (n = 6) to severe
(n = 6) somatic symptoms versus 15.38% with aMCI (n = 7 moderate, n = 1 severe).
The first hypothesis, there will be a significant negative relationship between time
since diagnosis and level of cognitive impairment from MCI, was not supported (r = 0.03,
p = 0.76).

In addition, although a significant difference was noted between aMCI and

naMCI on the MoCA (F(1,89) = 4.18, p = 0.04, MD = -1.46), mean levels of cognitive
impairment for both subtypes fell within the expected range for MCI on the MoCA (≤
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26). There were no significant relationships between the MoCA and other study
instruments, and all of those relationships were < 0.20 (table 3); consequently, scores on
the MoCA were excluded from further analyses.
The second study hypothesis, there will be significant positive relationships
between uncertainty and coping, was partially supported. Both uncertainty (USS-U) and
stress from uncertainty (USS-S) were significantly and positively correlated with problem
focused coping (BC-P), and dysfunctional coping (BC-D). However, the positive
relationship with emotion focused coping (BC-E) was not significant.
The third study hypothesis, there will be significant positive relationships between
uncertainty and psychological distress, was also partially supported. There were
significant positive relationships with both the USS-U and USS-S on depression (SQ-D),
anxiety (SQ-A), and anger/hostility (AQ-AH). However, somatic symptoms (SQ-S) only
had a significant positive correlation with the USS-S and not the USS-U.
The fourth study hypothesis, there will be significant positive and negative
relationships between coping and psychological distress, was also only partially
supported. Use of emotion focused coping strategies (BC-E) was positively correlated
with the other measures of coping, but it was not significantly correlated with uncertainty
or psychological distress (table 3). Given the significant relationships between the BC-E,
BC-P, and BC-D, the decision was made not to exclude BC-E from coping step of testing
the conceptual framework.
Four hierarchical multiple regression equations were constructed to assess the
final hypotheses and determine the fit of variables to predict each of the four
psychological distress variables in the conceptual model. MCI duration (Time) and
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MoCA were excluded from the analysis as it was determined that they were not strongly
related to psychological distress (see table 3); and these variables are not amenable to
modification by nursing intervention. Consequently, the hypotheses, (a) the relationships
between level of cognitive impairment from MCI and coping will be mediated by
uncertainty; and (b) the relationships between level of cognitive impairment from MCI
and psychological distress will be mediated by uncertainty and coping, were not
supported as they could not be assessed with the exclusion of MoCA from the analyses.
Age and MCI subtype were included as control variables in step one of each
analysis given their significant relationships between the variables in the models. The
USS-S was inserted to represent uncertainty in step 2, and BC-E, BC-P, and BC-D were
inserted in step 3 to represent coping. Finally, interaction terms for the subtypes of MCI
by USS-S, BC-E, BC-P, and BC-D were added to step 4 in order to assess for possible
differences by subtype of MCI in the strength and/or direction of the relationships
between the dependent psychological distress variables and the independent variables of
USS-S, BC-E, BC-P, BC-D.
All models significantly predicted psychological distress to some extent (table 4).
The weakest model predicted somatic symptoms where MCI subtype was a significant
predictor in each step, explaining approximately 9% of the variance in somatic
symptoms. Stress from uncertainty (USS-S) was a significant positive predictor in every
model indicating that as stress from uncertainty increases, psychological distress also
increases. The USS-S accounted for 40% of the variance in anxiety, 19% in depression,
18% in anger/hostility, and 5% in somatic symptoms. With the addition of coping, USSS remained a significant predictor in every model except somatic symptoms.
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The addition of coping helped to explain an additional 13% of the variance in
depression, 11% in anger/hostility, 7% in anxiety, and 4% in somatic symptoms.
Problem focused coping was not a significant predictor in any model. Dysfunctional
coping was a significant positive predictor in every model except somatic symptoms,
indicating that as use of dysfunctional coping strategies increases, psychological distress
also increases. Finally, emotion focused coping was a significant negative predictor only
in the model for anger/hostility, indicating that use of emotion focused coping reduces
anger/hostility. The significant predictive relationship between BC-E and SQ-AH was
somewhat unexpected given their lack of significant correlation, which suggests that their
relationship might be moderated by another variable. Considering that inclusion of
coping variables occurred in step 3 of the regression models, variables in steps 1 (age,
MCI subtype) and step 2 (USS-S) were investigated as potential moderating variables
between BC-E and SQ-AH. The regression analysis for SQ-AH was repeated with only
the interaction terms for BC-E and age, BC-E and USS-S, and BC-E and MCI subtype
added as step 4. The resulting model demonstrated a significant change between step 3
and 4 (F(3,81) = 2.95, p = 0.04, R2 change = 0.06), and both USS-S (β = -0.26, p = 0.01)
and age (β = -0.18, p = 0.05) were demonstrated to be significant moderating variables
between the BC-E and SQ-AH.
A significant change in R2 when interaction terms for MCI-subtypes were
included was apparent only in the model predicting anger/hostility. Upon further
exploration, a significant difference was detected in the strength but not direction of the
relationship between USS-S and SQ-AH for those with aMCI (r = 0.35, p = 0.01) versus
naMCI (r = 0.62, p < 0.001). Consequently, the final hypothesis, there will be no

120
significant differences between the subtypes of MCI in the strength and direction of
uncertainty, coping, and psychological distress, was not supported given the difference in
the relationship of USS-S and SQ-AH. This difference in the strength of relationship
and possible clinical implications is demonstrated by figure 2.
Sobel tests demonstrated that BC-D was the only significant mediating variable in
the regression models. BC-D provided significant partial mediation between the USS-S
and SQ-D (p < 0.01), SQ-A (p < 0.01), and SQ-AH (p < 0.03). It is important to note that
while the strength of the relationship between the USS-S and SQ-AH was significantly
different between MCI subtypes, the relationship between BC-D and SQ-AH was not
significantly different between the MCI subtypes.
Discussion

The results of this study support the hypothesized relationships between
uncertainty, coping, and psychological distress within the conceptual framework.
However, these results also suggested some possible areas for refining the framework.
The regression models indicated that (a) increased uncertainty and dysfunctional coping
resulted in increased psychological distress for older adults with MCI; (b) other than
somatic symptoms, the relationships between uncertainty and psychological distress are
mediated by dysfunctional coping; and (c) increased emotion focused coping resulted in
decreased anger/hostility only when older adults’ age and levels of uncertainty are
accounted for. These relationships are demonstrated in Figure 3.
Responses on the Brief Cope were similar to those reported with the same
instrument in other studies of persons with MCI in which participants also reported more
emotional focused coping than problem focused or dysfunctional coping (Lin & Heidrich,
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2012; McIlvane et al., 2008). The three coping subscales were all positively correlated
with both uncertainty and psychological distress variables as predicted by the framework,
but those relationships were not always significant as was found with the emotional
coping subscale. Dysfunctional coping was the most significant coping variable
predictive of psychological distress, and a significant mediating variable between
uncertainty and psychological distress. This finding suggests that interventions to
decrease uncertainty and psychological distress in persons with MCI might focus on
decreasing dysfunctional coping behaviors such as self-distraction, venting, self-blame,
denial, or behavioral disengagement.
Overall levels of uncertainty and stress from uncertainty were similar to findings
from the USS in women with breast cancer (Agretelis, 1999). As expected, items which
resulted in the most uncertainty were those that pertain to the unforeseeable future with
MCI. Conversely, items that resulted in the least uncertainty pertained to trust in
diagnosis (being told the truth), nurses and other health practitioners. This finding
highlights the certainty in being able to trust nurses and other health practitioners which
indicates the potential role they might provide to reduce uncertainty for older adults with
MCI. Many participants talked about items on the USS or told a story about an item
while completing the survey. In addition to making comments equating uncertainty with
worry or stress, some participants indicated that if a loved one was filling out their form,
or if they were receiving care at a different clinic, then they might indicate a higher
degree of uncertainty. Others reflected that they had never thought about the items on the
USS and had a desire to obtain more information about MCI. Such comments suggest
there might be potential differences in uncertainty from MCI based upon trust of the
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provider making the diagnosis of MCI, explanation of the diagnosis, and educational
materials provided.
Although mean responses on the psychological distress subscales fell within the
“normal range” for distress, 28.27% of the sample scored within the moderate to severe
range of distress. This finding is supported by previous research which found greater
levels of psychological distress, in particular depression and anxiety, in persons with MCI
compared to those without MCI or dementia (Petersen et al., 2014; Shahnawaz et al.,
2013). In addition, in this study, those with naMCI reported higher degrees of distress
than those with aMCI; however, this finding is not well supported by previous literature.
For example, one study found no significant differences in report of psychological
distress by MCI subtype (Lee, Cho, Hong, Kim, & Oh, 2008); and yet, in another study,
those with aMCI reported significantly more depression than those with naMCI
(Shahnawaz et al., 2013). One confounding factor not explored in this study is
differences in the amount and type of chronic conditions experienced between those with
aMCI versus naMCI which may result in differences of reported somatic symptoms.
This study includes a number of limitations. Recruiting subjects from one
academic-focused clinic in the Midwest and cross-sectional design resulted in a
homogeneous sample and limits generalizability of results. To address these concerns,
further research is needed with more diverse populations within different care settings
and areas of the US or other countries. Specific to cross-sectional limitations,
longitudinal studies will be needed to evaluate if the study variables change over time.
Finally, two instruments had not been used in older adults with MCI (USS, SQ). While
this study demonstrated acceptable alpha levels and may support the use of these

123
instruments in older adults with MCI, future studies will still be needed to support the
psychometrics demonstrated and determine the appropriateness of these instruments over
time.
Understanding the consequences of having MCI is foundational to designing
appropriate interventions that help to decrease uncertainty and dysfunctional coping, and
promote emotional focused coping in order to reduce psychological distress from MCI.
The Sjostedt framework provides direction to nurses involved in research with MCI, and
can also guide the development of interventions for the management of MCI. The
findings of this study demonstrates the framework’s proposed relationships between
uncertainty, coping, and psychological distress as a consequence of MCI, independent of
the level of one’s cognitive impairment. Important clinical considerations from this study
are the level of and differences in psychological distress between the subtypes of MCI
and the sources of uncertainty. Psychological distress frequently presents as somatic
symptoms in older adults but can be misattributed to chronic illnesses (National Ageing
Research Institute, 2009). Persons with naMCI need to be assessed for interventions
needed to address somatic symptoms of psychological distress. Interventions might
include educational materials and support groups should address concerns about the
future with MCI and offer guidance for future planning in order to reduce anxiety and
uncertainty.
This study provides preliminary evidence to support the hypothesized
relationships between the constructs in the Sjostedt framework for older adults with MCI.
The next step in validating the framework will be to replicate the study results with more
diverse samples over time and evaluate the potential interactions between the modifiable
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antecedents and the consequences of MCI. Given the cross-sectional nature of this study,
it is likely that if cognitive status were assessed over a given time rather than at one time
point, a significant relationship between cognition and the study variables might be
observed as it would allow for calculation of differences in cognition over time for each
participant. Future studies will also need to contain cognitive comparison groups to
further assess for the possible impact of cognitive impairment on uncertainty, coping, and
psychological distress. Finally, while the design of this study was not mixed methods,
several comments from participants were noted pertaining to the USS. It is important to
consider those comments in planning future studies or interventions focused on
uncertainty with MCI. For example, future studies might involve family members and/or
paid caregivers in the assessment of uncertainty or explore differences in the uncertainty
experienced between caregivers and older adults with MCI.
Notes

This study was funded by a $2,500 dissertation grant awarded by the Southeastern
Wisconsin Nursing Research Consortium. The authors would also like to thank the
neurology clinic staff for their assistance with participant recruitment, collection space,
and support.
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Tables and figures

Table 1
Theoretical constructs, instruments, and reliability by order of administration

Theoretical Construct

Instrument with Subscales

Scale

Cognitive Impairment

Montreal Cognitive Assessment

11 items

Total Scale
Select MCI Antecedents

0-30 points

Demographic Survey

Uncertainty Stress Scale

*Observed in this study

N/A

59 items

Uncertainty

0-316 points

0.85

Stress from Uncertainty

0-308 points

0.76

Coping

Psychological Distress

0.66

10 items
N/A points

Uncertainty

α*

Brief COPE

28 items

Emotion Focused

0-30 points

0.85

Problem Focused

0-18 points

0.86

Dysfunctional

0-36 points

0.76

Symptom Questionnaire

92 items

Depression

0-23 points

0.89

Anger/Hostility

0-23 points

0.83

Anxiety

0-23 points

0.89

Somatic

0-23 points

0.88

Total Scale

0-92 points

0.95
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Table 2.
Levels and differences of uncertainty, coping, and psychological distress for older adults

with aMCI vs naMCI (mean ± SD).

Variable

aMCI (n=52)

naMCI (n=39)

Total (n=91)

Range

21.52 ± 2.80

22.97 ± 3.99

22.14 ± 3.42

12-30

Uncertainty (USS-U)

90.49 ± 80.11

77.78 ± 53.16

85.04 ± 69.79

0-291.00

Stress of Uncertainty (USS-S)

84.06 ± 80.80

82.24 ± 63.71

83.28 ± 73.58

0-279.91

Emotion Focused Coping (BC-E)

11.54 ± 6.78

13.36 ± 6.99

12.32 ± 6.89

0-30

Problem Focused Coping (BC-P)

6.19 ± 4.29

7.28 ± 5.70

6.66 ± 4.94

0-18

Dysfunctional Coping (BC-D)

5.15 ± 4.62

6.44 ± 5.17

5.70 ± 4.88

0-20

Depression (SQ-D)

3.38 ± 4.22

3.69 ± 4.50

3.52 ± 4.32

0-17

Anxiety (SQ-A)

4.25 ± 4.76

4.64 ± 4.88

4.42 ± 4.79

0-21

Anger-Hostility (SQ-AH)

2.23 ± 2.69

3.54 ± 3.65

2.79 ± 3.19

0-13

*Somatic (SQ-S)

4.17 ± 3.65

6.90 ± 5.40

5.34 ± 4.66

0-21

14.04 ± 12.37

18.77 ± 15.64

16.07 ± 13.99

0-52

MoCA
Uncertainty Stress Scale:

Brief COPE:

Symptom Questionnaire:

Total Scale (SQ-T)

*Denotes significant difference, t-test (p = 0.005), between aMCI and naMCI
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Table 3.
Pearson’s correlations between instrument scales (n = 91).

Age

Time-

MoCA

MCI

USS-

USS-S

BC-E

BC-P

BC-D

SQ-D

SQ-A

U

SQ-

SQ-S

AH

Age

1

Time

0.06

1

MoCA

-0.23*

0.03

1

USS-

-0.07

-0.08

-0.05

1

USS-S

-0.20

-0.06

0.02

0.86**

1

BC-E

-

-0.07

-0.05

0.13

0.21

1

-0.19

0.06

0.21*

0.34**

0.72**

1

-0.13

0.05

0.35**

0.46**

0.42**

0.59**

1

U

0.45**
BC-P

0.47**

BC- D

0.34**

SQ-D

-0.18

-0.02

0.08

0.36**

0.47**

0.08

0.26*

0.51**

1

SQ-A

-0.26*

0.04

0.06

0.46**

0.67**

0.17

0.37**

0.55**

0.81**

1

SQ-

-0.18

0.07

0.17

0.35**

0.44**

0.01

0.21*

0.44**

0.57**

0.62**

1

-0.09

0.35**

0.16

0.08

0.23*

0.08

0.17

0.31**

0.44**

0.51**

0.46**

AH
SQ-S

Significant relationships shaded: *p < 0.05, **p < 0.01

1
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Table 4.
Testing of relationships between uncertainty, coping, and psychological distress (n = 91)

Depression
Variables1

Anxiety
β

B (SE)

Anger-Hostility
β

B (SE)

β

B (SE)

Somatic
β

B (SE)

Block 1: Control
(Constant)

10.89 (4.21)

Age

-0.10 (0.06)

-0.18

-0.15 (0.06)

-0.26*

-0.06 (0.04)

-0.15

-0.03 (0.06)

-0.05

MCI Type

-0.10 (0.92)

-0.01

-0.07 (1.00)

-0.01

-1.18 (0.67)

-0.19

-2.66 (0.96)

-0.28**

15.73 (4.59)

7.96 (3.06)

9.14 (4.42)

2

R Change

0.03

0.07

0.07

0.09

1.56

3.08*

3.04*

4.21**

F Ratio for
R2 Change
Block 2: Uncertainty

(Constant)

5.17 (3.98)

Age

-0.05 (0.05)

-0.09

-0.07 (0.05)

-0.12

-0.03 (0.04)

-0.07

-0.01 (0.06)

-0.01

MCI Type

-0.25 (0.83)

-0.03

-0.31 (0.76)

-0.03

-1.29 (0.60)

-0.20*

-2.74 (0.94)

-0.29**

USS-S

0.03 (0.01)

0.45***

0.04 (0.01)

0.65***

0.02 (0.01)

0.43***

0.02 (0.01)

0.23*

6.59 (3.66)

3.95 (2.91)

5.96 (4.53)

2

R Change

0.19

0.40

0.18

0.05

21.73***

65.72***

20.02***

5.18*

0.23 (0.20)

0.47 (0.45)

0.24 (0.21)

0.14 (0.11)

F Ratio for
R2 Change
2

R (Adjusted
R2)
Block 3: Coping

(Constant)

3.99 (4.51)

Age

-0.04 (0.05)

-0.07

-0.05 (0.05)

-0.08

-0.03 (0.04)

-0.09

0.02 (0.07)

0.03

MCI Type

0.01 (0.77)

0.00

-0.09 (0.73)

-0.01

-1.19 (0.58)

-0.19*

-2.56 (0.94)

-0.27**

USS-S

0.02 (0.01)

0.29**

0.03 (0.01)

0.52***

0.01 (0.01)

0.31**

0.01 (0.01)

0.14

BC-E

-0.13 (0.08)

-0.21

-0.12 (0.08)

-0.18

-0.14 (0.06)

-0.28*

-0.06 (0.10)

-0.09

BC-P

0.02 (0.13)

0.02

0.12 (0.12)

0.12

0.04 (0.09)

0.06

0.03 (0.15)

0.03

BC-D

0.38 (0.10)

0.43***

0.28 (0.10)

0.28**

0.22 (0.08)

0.34**

0.23 (0.13)

0.24

4.31 (4.23)

5.03 (3.36)

4.25 (5.50)

2

R Change

0.13

0.07

0.11

0.04
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F Ratio for
R2 Change

5.71***

4.42**

4.57**

1.39

0.36 (0.31)

0.54 (0.51)

0.35 (0.30)

0.18 (0.12)

2

R (Adjusted
R2)
Block 4: Interaction Terms (IT)

(Constant)

4.37 (4.63)

Age

-0.03 (0.06)

-0.06

-0.04 (0.05)

-0.08

-0.05 (0.04)

-0.13

0.01 (0.07)

0.01

MCI Type

0.01 (0.79)

0.01

-0.07 (0.73)

-0.01

-1.12 (0.56)

-0.18*

-2.52 (0.93)

-0.27**

USS-S

0.02 (0.01)

0.25

0.04 (0.01)

0.67***

0.03 (0.01)

0.66***

0.03 (0.01)

0.53**

BC-E

-0.19 (0.14)

-0.31

-0.12 (0.13)

-0.17

-0.05 (0.10)

-0.10

-0.02 (0.16)

-0.03

BC-P

0.01 (0.20)

0.01

0.05 (0.19)

0.05

-0.18 (0.14)

-0.27

-0.07 (0.24)

-0.08

BC-D

0.44 (0.17)

0.49**

0.23 (0.16)

0.23

0.33 (0.12)

0.50**

0.16 (0.21)

0.17

IT USS-S

0.01 (0.01)

0.02

-0.02 (0.01)

-0.23

-0.02 (0.10)

-0.43*

-0.04 (0.02)

-0.52**

IT BC-E

0.10 (0.17)

0.11

0.02 (0.16)

0.02

-0.11 (0.12)

-0.17

0.01 (0.20)

0.01

IT BC-P

0.05 (0.27)

0.04

0.17 (0.25)

0.11

0.31 (0.19)

0.31

0.16 (0.31)

0.11

IT BC-D

-0.06 (0.22)

-0.05

0.13 (0.20)

0.09

-0.17 (0.16)

-0.18

0.14 (0.26)

0.10

4.05 (4.27)

4.74 (3.27)

3.49 (5.44)

2

R Change

0.01

0.02

0.07

0.07

0.22

0.92

2.46*

1.78

0.37 (0.29)

0.56 (0.51)

0.42 (0.35)

0.25 (0.15)

F Ratio for
R2 Change
2

R (Adjusted
R2)

1

Note: MCI type coded as aMCI = 1, naMCI = 0

*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001
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Figure 1. The Sjostedt framework for older adults with MCI.
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Figure 2. Demonstration of the differences between aMCI and naMCI on the relationship
between stress from uncertainty and anger/hostility.

SQ-AH (Possible Range 0-23)

Differences between aMCI and naMCI on the
Relationship between Stress from Uncertainty
and Anger/Hostility
20
15 Severe (13-23)
10 Moderate (8-12)

Sig p=0.05

aMCI
naMCI

5
0 Normal (0-7)
0
308
USS-S (Possible Range 0-308)

*Note: Dashed lines represent separation between clinical levels of anger/hostility.
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Figure 3. Illustration of relationships within the conceptual framework.
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Table 3. Participant demographics (n=91).

Variable

aMCI (n=52)

naMCI (n=39)

Total (n=91)

76.13 ± 8.05

74.00 ± 8.19

75.22 ± 0.49

(58-89)

(58-88)

(58-89)

1.98 ± 1.87

2.86 ± 2.70

2.36 ± 2.29

(0-9.33)

(0-10)

(0-10)

Male, %

61.5%

61.5%

61.5%

Female, %

38.5%

38.5%

38.5%

Caucasian/White, %

94.2%

94.9%

94.5%

African American/Black, %

3.8%

5.1%

4.4%

Hispanic/Latino, %

1.9%

0%

1.1%

Married, %

76.9%

76.9%

76.9%

Widowed, %

5.8%

10.3%

7.7%

Divorced, %

7.7%

5.1%

6.6%

Single, %

7.7%

5.1%

6.6%

Dating/Engaged, %

1.9%

2.6%

2.2%

Catholic, %

40.4%

61.5%

49.5%

Lutheran, %

21.2%

17.9%

19.8%

Other Christian Religions, %

25.0%

10.3%

18.7%

Non-Christian Religions, %

3.8%

5.1%

4.4%

No religion, %

9.6%

5.1%

7.7%

Age (years), mean ± SD
(Range)
MCI Duration (years), mean ± SD
(Range)
Gender:

Race/Ethnicity:

Marital Status:

Religious Affiliation:
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Education (years), mean ± SD

15.16 ± 3.71

15.65 ± 3.28

15.37 ± 3.52

(4-25)

(12-27)

(4-27)

No (Retired), %

88.5%

82.1%

85.7%

Yes, %

9.6%

7.7%

8.8%

0%

7.7%

3.3%

No (Never Employed), %

1.9%

2.6%

2.2%

Employment (years), mean ± SD

28.07 ± 13.22

28.40 ± 14.83

28.21 ± 13.85

(2-55)

(7-60)

(2-60)

Office/Law/Sales, %

46.2%

53.8%

49.5%

Health/Education/Service, %

30.8%

23.1%

27.5%

Engineering/Manual, %

23.1%

23.1%

23.1%

(Range)
Currently Employed:

No (Disabled), %

(Range)
Current/Former Professions:

*Denotes significant difference, One-way ANOVA or χ2 (p < 0.05), between aMCI and
naMCI
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Table 4. Correlations and ANOVA: Relationships and group differences in instrument
variables by demographic variables (n = 91).
Bivariate

MoC

USS-

USS-

correlations

a

U

S

Age

-0.23*

-0.68

-0.20

-0.45**

MCI

0.03

-0.08

-0.06

Education

-0.03

-0.03

Employment

0.03

Gender
Marital

BC-

SQ-

SQ-

SQ-

D

D

A

AH

-0.47**

-0.34**

-0.18

-0.26*

-0.18

-0.09

-0.07

-0.19

-0.13

-0.02

0.04

0.07

0.35**

-0.01

0.19

0.11

-0.16

-0.16

-0.02

0.03

-0.10

-0.05

-0.08

-0.02

-0.18

-0.01

-0.09

-0.14

-0.16

-0.12

0.19

0.15

0.37

0.60

0.27

1.47

3.68

2.43

0.34

3.53

0.74

0.99

0.82

0.29

0.69

0.47

3.42**

1.51

1.12

0.94

Religion

0.38

0.19

0.47

2.44

0.98

1.92

0.24

0.36

0.70

1.18

Profession

0.50

0.23

0.18

0.48

2.73

1.77

0.57

0.54

1.66

0.20

BC-E

BC-P

SQ-S

Duration

F-Statistic

Status

Significant relationships shaded: *p<0.05, **p<0.01
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Table 5. Mean uncertainty and stress from uncertainty by items on the USS (n = 91)
Item

Mean

Mean Stress

“I am uncertain...”

Uncertainty

from Uncertainty

1.648

0.868

1.6

0.733

1.489

0.756

2. about the stability of my MCI

1.427

0.778

14. about my chances to be well

1.398

0.716

3. what caused my MCI

1.385

0.648

16. whether my symptoms can be

1.371

0.798

1.352

0.659

1.296

0.679

38. how long my symptoms will last

1.263

0.638

45. about the cause of my symptoms

1.262

0.595

36. whether I will have difficulty coping

1.253

0.663

15. whether my MCI situation will be the
same in 5 years
4. whether I will be able to maintain my
present level of functioning
17. whether my MCI situation will
interfere with my ability to do my usual
activities

controlled
5. about the present state of my MCI
situation
35. about the unpredictability of my
symptoms
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with my MCI situation
10. whether my MCI condition is under

1.23

0.58

33. about the seriousness of my condition

1.217

0.687

21. whether my MCI disorder will return

1.188

0.667

52. what to look for to check the state of

1.183

0.61

1.178

0.611

1.171

0.526

1.167

0.567

49. what symptoms I should be aware of

1.148

0.543

19. how to manage my symptoms

1.144

0.633

27. whether any changes brought about by

1.12

0.627

1.101

0.449

1.1

0.511

1.099

0.556

control

my MCI situation
11. whether my MCI condition will cause
me to have symptoms
50. about how to choose the treatments I
should have
6. what questions to ask my doctors
about my MCI situation

my MCI affects my relationships
12. what to say to others about my MCI
situation
7. whether changing my lifestyle will
help my condition
53. whether treatments will eliminate the
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MCI
41. what unusual symptoms mean in terms

1.088

0.488

1.088

0.55

1.082

0.424

1.077

0.516

1.071

0.583

1.068

0.648

1.063

0.594

1.049

0.568

1.047

0.494

1.038

0.526

0.988

0.458

of my MCI situation
51. whether following the treatment plan
recommended to me will help
30. whether I can depend on test results as
an indicator of my condition
8. how to make sense of what I am told
about my MCI
34. about my ability to handle my
emotions related to the MCI
1. whether changes in my mild cognitive
impairment (MCI) will be detected early
26. whether my treatments have corrected
my condition
28. whether my MCI situation will affect
my life goals
29. whether what I am doing about my
MCI situation will help me
9. about the effectiveness of my
treatments
23. about my understanding of the
treatments I have received or am receiving
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20. about choices made regarding my

0.953

0.424

0.952

0.422

54. how to manage my medical care

0.94

0.518

40. whether I would choose to have all the

0.936

0.462

0.92

0.48

0.878

0.463

37. about the quality of information I have

0.867

0.427

24. how to approach health care workers

0.835

0.353

0.816

0.447

0.809

0.337

0.753

0.395

treatments
13. about differing explanations I have
been given

treatments recommended to me
32. whether delays in treatment will
influence my chances of successful
recovery
42. whether they might find something
wrong when I go for a checkup

about my care (for example, nurses,
doctors, dietitians)
47. whether insurance can be obtained
because of my condition
22. about the adequacy of the follow-up I
am having
25. whether the MCI situation will be
involved in my death
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48. whether I can manage financially

0.735

0.434

0.729

0.4

18. about my doctor's(s') abilities

0.682

0.341

31. whether my MCI condition will affect

0.614

0.357

0.59

0.265

0.573

0.244

0.512

0.329

because of my condition
46. whether I can depend on people who
are important to me to be there when I
need them

my sex life
44. whether I will be well cared for by the
health professionals other than the nurses
43. whether I will be well cared for by the
nurses
39. whether I am being told the truth about
my MCI situation
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Table 6. Differences in bivariate correlations between instrument scales by MCI subtype
(n = 91).
1

aMCI

2

3

4

1

5

6

7

8

9

naMCI
1. USS-U

1

2. USS-S

0.86**

1

0.87**

3. BC-E

4. BC-P

5. BC- D

6. SQ-D

7. SQ-A

8. SQ-AH

9. SQ-S

0.19

0.34*

1

0.05

-0.01

0.23

0.43**

0.68**

0.26

0.25

0.76**

0.32*

0.52**

0.31*

0.44**

0.50**

0.39*

0.52**

0.72**

0.35*

0.51**

0.15

0.30**

0.57**

0.41*

0.41**

-0.02

0.22

0.45**

0.41**

0.68**

0.29*

0.47**

0.64**

0.82**

0.62**

0.68**

0.02

0.28

0.44**

0.80**

0.26

0.35*

-0.01

0.23

0.41**

0.64**

0.61**

0.60**

0.62**

-0.02

0.17

0.45**

0.53**

0.64**

-0.07

0.09

0.11

0.20

0.34*

0.34*

0.36**

0.31*

0.39*

0.44**

-0.01

0.11

0.24

0.56**

0.67**

0.52**

1

1

1

1

Significant relationships: *p<0.05, **p<0.01
Shaded areas indicate a difference of 0.1 or greater between aMCI and naMCI

1
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Table 7. Sobel Statistic (standard error) to test for mediation of coping variables between
uncertainty and psychological distress (n = 91).
Depression

Anxiety

Anger/Hostility

Somatic

BC-E

-0.64 (<0.01)

-0.28 (<0.01)

-1.03 (<0.01)

-0.08 (0.94)

BC-P

0.71 (<0.01)

1.29 (<0.01)

0.15 (<0.01)

0.64 (<0.01)

BC-D

2.84** (<0.01)

2.64** (<0.01)

2.56* (<0.01)

1.78 (<0.01)

*p<0.05, **p<0.01, ***p<0.001
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APPENDIX B: SUPPLIMENTAL FIGURES FOR MANUSCRIPT 2

Depression : Total Sample (n = 91)

Number of Subjects

30
25
20
15
10
5
0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Figure 14. Clinical distribution of depression (n = 91)
*Note: Green = Normal, Yellow = Moderate, Red = Severe
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Anxiety : Total Sample (n =91)

Number of Subjects

25
20
15
10
5
0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Figure 15. Clinical distribution of anxiety (n = 91).
*Note: Green = Normal, Yellow = Moderate, Red = Severe
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Hostility : Total Sample (n = 91)

Number of Subjects

30
25
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0
0
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7

8

9

10 11 12 13

Figure 16. Clinical distribution of hostility (n = 91).
*Note: Green = Normal, Purple = Moderate, Red = Severe
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Somatic : Total Sample (n = 91)
16
Number of Subjects

14

12
10
8
6
4
2
0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Figure 17. Clinical distribution of somatic symptoms (n = 91).
*Note: Green = Normal, Purple = Moderate, Red = Severe
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Depression between aMCI and naMCI
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9 10 11 12 13 14 15 16 17
naMCI

Figure 18. Distribution of depression by aMCI and naMCI (n = 91).
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Anxiety between aMCI and naMCI
15

10
5
0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
aMCI

naMCI

Figure 19. Distribution of anxiety by aMCI and naMCI (n = 91).
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Hostility between aMCI and naMCI
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Figure 20. Distribution of hostility by aMCI and naMCI (n = 91).

13
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Somatic between aMCI and naMCI
10
8

6
4
2
0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
aMCI

naMCI

Figure 21. Distribution of somatic by aMCI and naMCI (n = 91).
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Dysfunctional Problem

Emotion

Distribution of Coping
Acceptance
Emotional Support
Religion
Positive Reframing
Humor
Active Coping
Planning
Instrumental Support
Self-Distraction
Venting
Self-Blame
Denial
Behavioral Disengagement
Substance Use
0

1

2

Figure 22. Distribution of coping behaviors (n = 91).
Note: 0 = Not at all, 1 = A little bit, 2 = A medium amount, and 3 = A lot.

3
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Figure 23. Interaction plot of USS-S on the relationship of BC-E and SQ-AH.
Note: Y = SQ=AH, X = BC=E, CVz(1) = USS-S Mean + SD, CVz(2) = USS-S Mean,
CVz(3) = USS-S Mean – SD
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Figure 24. Interaction plot of age on the relationship of BC-E and SQ-AH.
Note: Y = SQ=AH, X = BC=E, CVz(1) = Age Mean + SD, CVz(2) = Age Mean, CVz(3)
= Age Mean – SD

178
APPENDIX C: STUDY FORMS

The following appendix pages contain a copy of the consent form, recruitment flyer, and
study instruments.
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Human Subjects Consent Form

Please note, while the Institutional Review Board process has been started, approval has

not yet been obtained for the following consent document.

CONSENT TO PARTICIPATE IN RESEARCH

Name of Study Subject: ____________________________

Consequences of mild cognitive impairment.

Jennifer Sjostedt, Marquette University PhD-Student and Dr. Malgorzata Franczak Marquette
University with the Department of Neurology

414-805-5224 Medical College of Wisconsin 8701 Watertown Plank Road

Milwaukee WI 53226

You are invited to take part in this research study. This form tells you why this research study is
being done, what will happen in the research study, possible risks and benefits to you, your
choices, and other important information. If there is anything that you do not understand, please
ask questions. Then you can decide if you want to join this study or not.

A1. INTRODUCTION – WHY ARE WE ASKING YOU ABOUT THIS STUDY?

You are being invited to participate in this research study because you have been given a
diagnosis of Mild Cognitive Impairment (MCI). Because of your diagnosis of MCI, you may be
eligible for a research study which is investigating how people with MCI experience uncertainty,
coping, and psychological distress (like depression).
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A total of about 130 people are expected to participate in this study all at the Medical College of
Wisconsin/Froedtert Hospital.

The Director of the study is Jennifer Sjostedt with Dr. Malgorzata Franczak in the Department of
Neurology and at Marquette University. You can ask who these people are.

At this time, no funding has been received for this study.

A2. DO I HAVE TO BE IN THIS STUDY?

You can decide whether to take part in this study or not. You are free to say yes or no. Even if
you join this study, you do not have to stay in it. You may stop at any time.

A3. WHY IS THIS RESEARCH STUDY BEING DONE?

In this study we want to find out more about the consequences of having MCI. The only way to
find this out is to survey people with MCI about their levels of uncertainty, coping, and
psychological distress from having a diagnosis of MCI.

B1. WHAT WILL HAPPEN IF I TAKE PART IN THE STUDY? Summary of study procedures:

To participate in this study, you will be asked to complete a number of directed paper and pencil
surveys. Jennifer Sjostedt, a PhD student from Marquette University, or a hired research assistant
from Marquette University will assist you with completing the surveys. Prior to starting the
surveys, if you were not tested during your normal clinic visit using the Montreal Cognitive
Assessment, you will first be screened using that instrument to make sure you fit the study’s
requirements. Next, you will be asked questions about your age, gender, educational level, marital
status, religious beliefs, income, and profession. Finally, you will be given 3 surveys to complete
regarding uncertainty, coping, and psychological distress. It is expected that participation in the
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study will take up to 45 minutes. Data will be recorded for the study on an electronic password
protected file with no identifying information such as your name, clinic visit date, or birthdate.

B2. HOW LONG WILL I BE IN THE STUDY?
Participation in this study will be a one-time commitment of up to 45 minutes.

B3. CAN I STOP BEING IN THE STUDY?

You are free to quit the study at any time. If you are thinking about quitting, please tell the study
director.

The director can tell you about the effects of stopping, and you and the doctor can talk about what
follow-up care would help you the most.

The study director may take you out of this study at any time. This would happen if:
•

They think it is in your best interest.

•

You do not follow the study rules.

•

The whole study is stopped.

If this happens, the study director will tell you.

C1. WHAT RISKS OR PROBLEMS CAN I EXPECT FROM THE STUDY?

We watch everyone in the study for unexpected problems. You need to tell the study director or a
member of the study team immediately if you experience any problems or become too upset.
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C2. RISKS OF PARTICIPATION

You may feel that some of the questions we ask are stressful or upsetting. If you do not wish to
answer a question, you may skip it and go to the next question, or you may stop immediately.
You will also be asked some questions about psychological distress, which may tell us if you are
potentially experiencing depression. If your responses suggest that you might be experiencing
depression, we will request your permission to inform your physician in the Neurology
Department that you may be experiencing depression, so that they might follow-up with you on
treatment of depression.

C4. ARE THERE ANY BENEFITS TO TAKING PART IN THE STUDY?

This study will not help you, but we hope the information from this study will help us provide
better health services for persons with MCI.

D1. ARE THERE ANY COSTS TO BEING IN THE STUDY?
There are no costs to you for participating in this study.

D2. WILL I BE PAID FOR PARTICIPATING IN THE STUDY?

If funding is received for this study, you will be compensated for participation with a $10 Pick-nSave gift card.

D3. WHAT OTHER CHOICES DO I HAVE?
You do not have to join this study. You are free to say yes or no.

If you do not join this study, your usual medical services will not change.

D4. WILL I BE GIVEN NEW INFORMATION ABOUT THE STUDY?
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If we learn any important new information [about the intervention] that might change your mind
about being in the study, we will tell you about it right away. You can then decide if you want to
stay in the study.

D5. WHAT HAPPENS IF I AM HARMED BECAUSE I TOOK PART IN THE STUDY?

No funds have been set aside to pay any costs if you are harmed because of this study. If you
think that you were harmed because of this study, let the study director, Jennifer Sjostedt know
right away by calling (414)-810-2756. By signing this form, you do not give up your right to seek
payment for harm you receive while participating in this study.

D6. WHO CAN ANSWER MY QUESTIONS ABOUT THE STUDY?

•
If you have more questions about this study at any time, you can call Dr. Franczak at
414-805-5224.

•
If you have questions about your rights as a study participant, want to report any
problems or complaints, obtain information about the study, or offer input, you can call the
MCW/Froedtert Hospital Research Subject Advocate at 414-456-8844.

E. PERMISSION TO COLLECT, USE AND SHARE HEALTH INFORMATION E1. What
health information will be collected and used for this study?

To do this research study, we need your permission to collect and use some health information
from you, or you cannot be in the study. This information may come from questions we ask,
forms we ask you to fill out, or your medical record, as described below. We will only collect and
use information needed for the study.

The health information we will collect and use for this study is:
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Health information collected during this study such as questionnaires, and performance on
cognitive testing.

Medical records dating from when you join this study until the end of the study.

E2. Who will see the health information collected for this study?

The only people allowed to handle your health information are those on the study team at the
Medical College of Wisconsin/Froedtert Hospital and at Marquette University, those on the
Institutional Review Board (IRB) and those who check on the research activities to make sure the
hospital’s rules are followed.

The study team may share your information with people who are not part of the study team
because they planned, pay for, or work with us on this study. If this happens, the federal Privacy
Rule may no longer protect your health information. For this study, we plan to share information
with those doctors, researchers or government representatives working with us on this study at the
institutions or companies listed here: Marquette University, Milwaukee, WI.

We may record your research information, including results of tests, procedures or questionnaires
done for research, in your Froedtert Hospital and/or Medical College of Wisconsin medical
record. As a result, this research information may be seen by people allowed to see your medical
records for healthcare operations or treatment; by those you allow to see your medical records by
giving written permission; and by others when required by law.

We will not use your personal health information for a different study without your permission or
the permission of a hospital research review board (IRB). Once all personal identification is
removed, the information might be used or released for other purposes without asking you.

Results of the study may be presented in public talks or written articles, but no information will
be presented that identifies you.

E3. What are the risks of sharing this health information?
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One risk of taking part in a research study is that more people will handle your personal health
information collected for this study. The study team will make every effort to protect the
information and keep it confidential, but it is possible that an unauthorized person might see it.
Depending on the kind of information being collected, it might be used in a way that could
embarrass you or affect your ability to get insurance. If you have questions, you can talk to the
study director about whether this could apply to you.

E4. How long will you keep the health information for this study?

If you sign this form, we plan to keep your information for 3 years in case we need to check it
again for this study.

E5. Can I cancel my permission to share this health information?

If you change your mind later and do not want us to collect or share your health information, you
need to send a letter to Dr. Malgorzata Franczak at 9200 W. Wisconsin Avenue, Milwaukee, WI
53226. The letter must say that you have changed your mind and do not want the researcher to
collect and share your health information. At that time, we may decide that you cannot continue
to be part of the study. We may still use the information we have already collected. If your health
information is no longer identified as yours, it is not possible to remove it from the study.

CONSENT TO PARTICIPATE IN THE STUDY

By signing my name below, I confirm the following:

•
I have read (or had read to me) this entire consent document. All of my questions have
been answered to my satisfaction.

•

The study’s purpose, procedures, risks and possible benefits have been explained to me.
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•

I agree to let the study team use and share the information gathered for this study.

•
I voluntarily agree to participate in this research study. I agree to follow the study
procedures as directed. I have been told that I can stop at any time.

IMPORTANT: You will receive a signed and dated copy of this Consent Form. Please keep it
where you can find it easily. It will help you remember what we discussed today.
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Recruitment Flyer

Have you been told that you have mild cognitive impairment
(MCI)?
Are you willing to share some details of your experience with
it?
After your normal clinic appointment today you will have the
opportunity to talk with a student researcher from Marquette University who
is interested in learning more about the consequences of having a diagnosis
of mild cognitive impairment. The study involves a one-time guided
interview using paper questionnaires, which may take up to 30 minutes total
to complete. Please let your physician or nurse know if you would like to
hear more about the study, and the student researcher will visit with you
after your appointment today!
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Instruments

Copies of all scoring instructions and study instruments are included in the order
that they will be administered. Starting on the next page, you will find the scoring
instructions (where applicable) followed by study instruments in this order:
(1) Montreal Cognitive Assessment (Nasreddine, 2011)
Obtained from www.mocatest.org
(2) Demographic Survey
(3) Uncertainty Stress Scale (Hilton, 1994)
(4) BriefCOPE (Carver, 1997)
Obtained from http://www.psy.miami.edu/faculty/ccarver/sclBrCOPE.html
(5) Symptom Questionnaire (Kellner, 1987)
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Demographic Questionnaire

Questions
1. What is your gender (Male, Female)?
2. What is your age (Years)?
3. What is your race/ethnicity
(Caucasian/White, African
American/Black, Hispanic/Latino, Asian,
Other)?
4. Are you single, married, divorced or
widowed?
5. How many years of school have you
completed?
6. What, if any, is your religious
affiliation? (i.e. Catholic, Muslim,
Methodist, etc)
7. Are you currently employed? (Yes/No)
8. What do you (or did you) do for work?
9. How long have you been in (or were in)
that profession?
10. Which of the following best describes
your annual income:
Under $25,000
$25,001 – 49,999
$50,000 – 74,999
$75,000 – 99,999
$100,000 – 149,999
Over $150,000
Prefer not to say
11. When were you diagnosed with MCI?
(Month/Year)

Answers
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BreifCOPE
Retrieved from: http://www.psy.miami.edu/faculty/ccarver/sclBrCOPE.html
Instructions:
The Brief COPE contains 28 items which assess fourteen coping reactions (with two
items for each for each reaction): active coping, planning, positive reframing, acceptance,
humor, religion, using emotional support, self distraction, denial, venting, substance use,
behavioral disengagement, and self-blame (Carver, 1997). The fourteen coping reactions
can be reduced into three sub-scales of coping: (1) emotion-focused coping (acceptance,
emotional support, positive reframing, religion, and humor); (2) problem-focused coping
(active coping, planning, instrumental support); and (3) dysfunctional coping (selfdistraction, venting, self-blame, behavioral disengagement, denial, and substance use)
(McIlvane et al., 2008).
Scales are computed as follows by totaling participant responses (with no reversals of
coding):
Sub-scales
Emotion-focused coping

Coping reactions and instrument items
Use of emotional support, items 5 and 15
Positive reframing, items 12 and 17
Humor, items 18 and 28
Acceptance, items 20 and 24
Religion, items 22 and 27

Problem-focused coping

Active coping, items 2 and 7
Use of instrumental support, items 10 and 23
Planning, items 14 and 25

Dysfunctional coping

Self-distraction, items 1 and 19
Denial, items 3 and 8
Substance use, items 4 and 11
Behavioral disengagement, items 6 and 16
Venting, items 9 and 21
Self-blame, items 13 and 26

Instrument:
These items deal with ways you've been coping with the stress in your life since you
found out you have mild cognitive impairment. There are many ways to try to deal with
problems. These items ask what you've been doing to cope with this one. Obviously,
different people deal with things in different ways, but I'm interested in how you've tried
to deal with it. Each item says something about a particular way of coping. I want to
know to what extent you've been doing what the item says. How much or how
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frequently. Don't answer on the basis of whether it seems to be working or not—just
whether or not you're doing it. Use these response choices. Try to rate each item
separately in your mind from the others. Make your answers as true FOR YOU as you
can.
1 = I haven't been doing this at all
2 = I've been doing this a little bit
3 = I've been doing this a medium amount
4 = I've been doing this a lot
1. I've been turning to work or other activities to take my mind off things.
2. I've been concentrating my efforts on doing something about the situation I'm in.
3. I've been saying to myself "this isn't real.".
4. I've been using alcohol or other drugs to make myself feel better.
5. I've been getting emotional support from others.
6. I've been giving up trying to deal with it.
7. I've been taking action to try to make the situation better.
8. I've been refusing to believe that it has happened.
9. I've been saying things to let my unpleasant feelings escape.
10. I’ve been getting help and advice from other people.
11. I've been using alcohol or other drugs to help me get through it.
12. I've been trying to see it in a different light, to make it seem more positive.
13. I’ve been criticizing myself.
14. I've been trying to come up with a strategy about what to do.
15. I've been getting comfort and understanding from someone.
16. I've been giving up the attempt to cope.
17. I've been looking for something good in what is happening.
18. I've been making jokes about it.
19. I've been doing something to think about it less, such as going to movies,
watching TV, reading, daydreaming, sleeping, or shopping.
20. I've been accepting the reality of the fact that it has happened.
21. I've been expressing my negative feelings.
22. I've been trying to find comfort in my religion or spiritual beliefs.
23. I’ve been trying to get advice or help from other people about what to do.
24. I've been learning to live with it.
25. I've been thinking hard about what steps to take.
26. I’ve been blaming myself for things that happened.
27. I've been praying or meditating.
28. I've been making fun of the situation.
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